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Summary 
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiological agent of Kaposi’s sarcoma (KS), a 
tumor of endothelial origin predominantly affecting immunosuppressed individuals. Up to date, 
vaccines and targeted therapies are not available. Screening and identification of antiviral compounds 
are compromised by the lack of scalable cell culture systems reflecting properties of virus transformed 
cells in patients. Further, the strict specificity of the virus for humans limits the development of in 
vivo models.  
In this study conditionally immortalized human endothelial HuARLT cells were validated as a system 
to study KSHV-induced pathogenesis and testing of novel antiviral drugs. Systematic analysis of 
cellular marker expression as well as cellular functions in 2D and 3D cell culture conditions showed 
that HuARLT cells closely mimic KSHV infection of primary cells. A humanized mouse model for 
KSHV based on the cell line develop lesions which histologically resemble KS. Importantly, invasive 
properties and tumor formation were completely reverted by purging cells from KSHV confirming for 
the first time that tumor formation is primarily dependent on viral infection, rather than being a 
consequence of irreversible transformation of the infected cells. 
The cell line was used to investigate the molecular mechanisms of KSHV maintenance in endothelial 
cells. This study proved that lack of cell proliferation is not sufficient to maintain the episomal virus, 
as was believed before. Rather, it demonstrated that 3D culture conditions (in vitro or in vivo) are 
required for efficient viral maintenance. Transcriptome analysis and pharmacological studies showed 
that increased activity of the PI3K/mTOR pathway governs viral maintenance in 3D cell culture, 
likely due to increased viral reactivation and favorable conditions for viral transmission. At the same 
time, inhibitor studies indicate that the DNA damage response associated MRN complex restricts viral 
maintenance in 2D, but not 3D cell culture. MRN-dependent episome degradation might thus be a 
second mechanism contributing to the differential viral maintenance in 2D and 3D cell culture 
conditions. 
A subset of 26 compounds from a natural compound library was screened for reducing the episomal 
viral copy number and the tumorigenic properties of KSHV-infected cells in 2D and 3D in vitro cell 
culture systems. Selected compounds were subsequently tested for the ability to reduce the tumor size 
in xenotransplanted mice. Based on the assay three drug candidates, namely pretubulysin D, 
epothilone B and chondramid B showed significant tumor reduction, with comparable or even higher 
efficiencies than rapamycin, a drug that was proposed for treatment of Kaposi’s sarcoma. 
Thus, this study shows that the combined use of antiviral and antitumor assays based on the same cell 
system is indicative for tumor reduction in vivo and therefore allows faithful selection of novel drug 
candidates against Kaposi’s sarcoma. 
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1. Introduction 
Kaposi’s sarcoma (KS) is a skin tumor which was named after a Hungarian dermatologist who in 
1872 first described cases of “idiopatic multiple pigmented sarcoma of the skin”. It was an 
extraordinary observation at the time and for many years the tumor was considered to be a rare 
disease of elderly men of Mediterranean origin1. In 1981, Alvin Friedman-Kein reported of an 
aggressive form of the disease in human immunodeficiency virus (HIV) infected men2, which 
eventually was classified as HIV-associated (epidemic) Kaposi's sarcoma. With the advent of HIV the 
incidence of KS with bad prognosis dramatically increased and the tumor was recognized as one of 
the AIDS-defining malignances. In 1994, Chang and Moore isolated the etiological agent, a new 
human herpesvirus, called Kaposi’s sarcoma associated herpesvirus (KSHV), or human herpesvirus 
83. Later, the virus was also associated with two lymphoproliferative disorders: primary effusion 
lymphoma and multicentric Castleman’s disease. The International Agency for Research on Cancer 
classifies KSHV as a class I carcinogen4.  
1.1 Structure and biology of Kaposi’s sarcoma associated herpesvirus 
1.1.1 Virus structure 
Based on phylogenetic analysis, KSHV is classified as a genus Rhadinovirus of the gamma-2 
herpesvirus subfamily in the family Herpesviridae5. Morphologically KSHV resembles herpes 
simplex virus 1 and human cytomegalovirus. Viral particles are 100-150 nm with a lipid envelope 
surrounding the tegument and the capsid. The envelope is represented by a lipid bilayer incorporating 
the viral glycoproteins ORF4, gB, gH/gL, gM/gN, and gpK8.16. 3D analysis of the capsid revealed 
that it is composed of hexamers and pentamers formed by the major capsid protein (ORF25) and the 
small capsid protein (ORF65)7,8 (Fig. 1.1 A and B).  
KSHV has a double-stranded genome, which is approximately 165 kB long and consists of a single, 
continuous unique region flanked on either side by a terminal repeat (TR) region. The unique region is 
140,5 kB long and encodes 87 predicted ORFs which include genes for structural proteins, replication 
enzymes as well as genes for untranslated RNAs and miRNAs (Fig. 1.1 C). The terminal repeat region 
consists of a variable number of repeats with high G:C content9. It contains two binding sites for the 
latent nuclear antigen (LANA) and the latent origin of replication. By binding to multiple TRs LANA 
tethers the circular viral episome to the host chromosome by binding nucleosomes through the folded 
region of histones H2A-H2B and ensures transmission of the episome to daughter cells during 
mitosis10,11.  
1. Introduction 
11 
 
  
 
1.1.2 Hosts and viral tropism 
Humans are the natural hosts of KSHV. Except humans, only common marmosets, New World 
Primates, are susceptible for KSHV. In these animals, the infection reflects the course and pathology 
Figure 1. 1 Structure of KSHV.  
A) Schematic representation of the viral capsid.  B) the enlarged view on the virus capsid (reprinted from7 with a permit 
from American Society for Microbiology. Copyright © 2000, American Society for Microbiology). Capsomers are 
indicated with an arrow. C) The structure of the KSHV episome. Kaposi's sarcoma-associated herpesvirus (KSHV) 
encodes 87 open reading frames (ORFs) and at least 17 microRNAs (purple boxes). Putative latent transcripts are 
indicated in green. Viral lytic genes are indicated in blue, cellular orthologs are highlighted with yellow boxes. (The 
figure is reprinted from12 with a permit from Springer Nature, licence Nr. 4380940529605. Copyright 2010 by Springer 
Nature)  
A 
C 
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observed in human, including the formation of skin KS-like lesions13. In humans the KSHV genome 
and its transcripts were detected in endothelial cells, B cells, macrophages, dendritic cells, 
oropharynx, prostatic epithelium, and keratinocytes6.  
1.1.3 Virus entry and early events 
KSHV recognizes two categories of cellular receptors, binding and entry receptors. The interaction 
between binding receptors, ubiquitously expressed cellular heparan sulfate (HS), and viral 
glycoproteins enables viral attachment and concentration on target cells. The interaction between 
cellular HS and viral glycoproteins promotes conformational changes and allows the access to 
adjacent cellular receptors. The entry receptors are cell-type specific and vary according to cell type 
and include cellular integrins, CD98, DS-SIGN, Eph2A (Table 1.1)14,15.  
 KSHV utilizes diverse endocytic pathways for entry into the target cells. Macropinocytosis is the 
major route of infection in endothelial cells16, whereas the clathrin-mediated endocytosis is utilized to 
enter B-cells and fibroblasts17. Enveloped viral particles are detected in cellular cytoplasm at 5 
minutes post infection and reach the nuclear periphery within 15 minutes p.i16. KSHV infection 
induces aggregation and thickening of microtubules. Virus capsid colocalizes with microtubules in a 
PI3K- and Rho-GTPase dependent manner. Rho-GTPase is involved in acetylation and aggregation of 
microtubules, which is crucial for the delivery of the viral genome to the nucleus18.  
KSHV penetrates the host cells and delivers its DNA as early as 15 minutes after infection with a 
peak at 90 minutes18–20. Following delivery to the nucleus, rapid circularization of the DNA occurs 
Table 1.1 Binding, entry receptors and mode of entry of KSHV in various target cells (adapted from 14,15) 
Target cells Binding receptors Entry receptors Mode of entry 
Endothelial cells HS Integrins ɑ3β1, 
ɑVβ3, ɑVβ5, 
CD98, Eph2A 
Macropinocytosis 
B cells, macrophages, 
dendritic cells 
DC-SIGN DC-SIGN Clathrin-mediated 
endocytosis 
 
Monocytes HS, DC-SIGN DC-SIGN, 
Integrins ɑ3β1, 
ɑVβ3, ɑVβ5 
 
Fibroblasts HS Integrins ɑ3β1, 
ɑVβ3, ɑVβ5, 
CD98, Eph2A 
Clathrin-mediated 
endocytosis 
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and within the host nucleus the virus exists in the episomal form. Viral gene expression starts as early 
as 30 minutes after the infection. Transcriptome analysis of human PBMC, CD14+ and endothelial 
cells revealed that a number of viral transcripts, including polyadenylated nuclear (PAN) RNA, 
ORF58/59, kaposin B, K2, K4, K6, ORF11, ORF17, ORF45, ORF27, ORF37, ORF57, ORF64, 
ORF65, ORF73, and T0.7 accumulate in the infected cells at 4 hours post infection. The majority of 
viral transcripts, however, get decreased at 24 hours p.i. whereas, the expression of ORF73 (LANA) 
becomes predominant21.  
1.1.4 Latent KSHV infection  
Like the other members of the γ-herpesvirus family, KSHV exhibits two different phases of infection: 
a persistent latent infection and a transient lytic reactivation that are distinguished by the viral gene 
expression patterns (see Figure 1.2. for a summary). During the predominant latent stage of the 
infection, the viral genome is maintained as a circular episome within the host cell nucleus with 
highly restricted protein expression and no production of virus particles.  
Latent viral transcripts are derived from a single genomic region, the so called latency locus, and 
include LANA, vCyclin, viral FLICE-inhibitory protein (vFLIP), Kaposins, as well as 18 miRNAs. 
These transcripts promote cell growth, evasion of apoptosis as well as proangiogenic and 
inflammatory signals12. During the latent stage of infection, LANA does not only tether KSHV 
episome to the cellular chromosome thereby ensuring viral maintenance11, but also regulates the 
expression of ORF5022–24, the key protein required for lytic reactivation.  
Viral latent proteins directly contribute to KSHV-induced tumorigenesis. LANA interferes with 
several anti-tumorigenic pathways, including p5325,26, RB-E2F27, and TGFβ28 as well as contributes to 
virus-induced angiogenesis by stabilizing HIF1ɑ29. vFLIP is responsible for spindle cell 
transformation of endothelial cells in vitro30. It activates NF-κB by direct binding to inhibitor of κB 
kinase ɣ31, which leads to suppression of apoptosis by activation of BCL-2 and BCL-X32. Kaposin A 
induces tumorigenic transformation of the cells and leads to formation of high-grade, highly vascular, 
undifferentiated sarcomas upon subcutaneous injection of Kaposin-transfected cells to athymic nu/nu 
mice33. Transgenic mice expressing LANA, vFLIP, or Kaposin A develop lymphoproliferative 
malignancies, indicating that the viral transcripts induce lymphatic cell proliferation. However, the 
induced tumors fail to exhibit the typical morphological features, suggesting that the latent viral genes 
alone are not sufficient to transform the cells12.  
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Figure 1. 2 KSHV biphasic life cycle and the genes expressed during latency and lytic reactivation.  
Reactivation can occur when the promoter of ORF50 is activated, resulting in the expression of replication and 
transcription activator (RTA), the main regulator for the viral lytic replication program. Early lytic genes include those 
encoding viral proteins required for DNA replication or viral gene expression, whereas late lytic genes are those 
encoding viral structural proteins, such as envelope and capsid proteins, that are required for assembly of viral particles 
(virions). 
 
1.1.5 Lytic reactivation 
The latent phase is reversible and certain environmental and physiological factors including oxidative 
stress34,35, hypoxia29,36, inflammatory cytokines37, co-infection38,39, and histone deacetylase 
inhibition40,41 may periodically reactivate the virus. Unlike latent replication, lytic replication is 
initiated from another origin of replication42, relying on specific KSHV-encoded transcription factors. 
Lytic reactivation proceeds via a rolling circle mechanism and leads to rapid multiplication of viral 
genome. Viral lytic reactivation results in the production of the virus particles which are released by 
cell lysis. It requires the activation of another virus-encoded set of ORFs in a temporally regulated 
cascade.  
Depending on the time of induction the lytic genes can be classified to the immediate early, early, and 
late lytic genes37. Immediate early genes require no previous viral gene expression and encode viral 
proteins that are directly involved in gene transcription as well as cellular modifications for viral 
replication. They include ORF50 (replication and transcription activator, RTA), ORF45, 
K4.2/K4.1/K4, ORF48, ORF29b, K3, ORF70, PAN, and k-bZIP43. ORF50-encoded RTA is a key 
regulator for lytic reactivation from the latency and its expression is both necessary and sufficient for 
viral reactivation. Ectopic expression of RTA in latently infected B-lymphocytes results in completion 
of the cascade leading to KSHV lytic replication44–46. k-bZIP is not required for lytic reactivation, 
however, it is needed for viral DNA replication, as k-bZIP together with RTA binds the lytic Ori 
promoter and initiates viral replication47.  
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RTA induces the expression of early viral genes. Early genes are expressed 10-24 hours post-
induction and include genes comprising the viral replication machinery as well as genes evading 
innate immune response. The genes encoding for viral structural proteins (capsid proteins, tegument 
protein, envelope glycoproteins, and relevant auxiliary factors) are initiated 48 hours post induction, 
and they are referred to as late genes. Expression of this final fraction of viral genes results in the 
assembly of viral particles and release of the virus from the infected cell43.  
Although the classic view on KSHV clearly divides its life cycle into two separate states with distinct 
gene expression patterns, recently, an independent transcriptional program has been described in 
KSHV infected lymphatic endothelial cells (LECs). It comprises the expression of several lytic genes, 
including ORF45, but lacks the full lytic program and does not result in the production of viral 
particles. The study indicated that this unique transcription program confers a selective sensitivity of 
infected cells to Rapamycin, observed in KSHV-infected LECs, but not blood endothelial cells48. This 
suggests that besides classically defined lytic and latent programs, the virus is able to establish also an 
intermediate state in LECs, referred to as relaxed latency49. 
1.2 Kaposi’s sarcoma – a virus induced tumor of endothelial origin 
1.2.1 Epidemiological aspects of Kaposi’s Sarcoma 
Unlike other herpesviruses with equally high seroprevalence around the globe, KSHV prevalence has 
a geographical distribution. It is generally low (less then 10%) in Northern Europe, the USA and Asia, 
elevated in the Mediterranean region (10-30%) and high in sub-Saharan Africa (25-85%)4. KSHV is 
primarily transmitted via saliva. The virus can be transmitted between family members as well as 
sexually transmitted and transmitted via blood transfusion and injecting drug use4,50.  
Kaposi’s sarcoma  is divided into 4 epidemiological forms: 1) classic KS affecting elderly men in 
Mediterranean region, 2) endemic KS observed Central and eastern Africa, 3) iatrogenic KS, 
developing after organ transplantation, 4) epidemic, or AIDS-KS12. The histological features of the 
four epidemiological forms of KS are indistinguishable12,51. Although infection with KSHV is a 
prerequisite to development of Kaposi’s sarcoma, the infection only is not sufficient and requires 
cofactors. The most important cofactor is immunosuppression. When KS incidence in the general 
population is 0.3:100,00052, it is highly increased in patients with HIV from 1:20, climbing up to 1:3 
in HIV-infected homosexual men before introduction of highly active antiretroviral therapy 
(HAART)12,53. Transplant KS appears to be more common in kidney transplant patients and has been 
estimated to occur in approximately 0.6-5.3% of solid organ transplants depending on the region54. It 
is the second most common cancer after prostate cancer in men in Uganda, where incidence rate is up 
to 30:100,00055. 
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1.2.2 KS histogenesis 
Clinically the lesions have been classified to four stages: patch, plaque, nodule, and tumor. The 
lesions comprise the spindle cells, (tumor cells), immature blood vessels, and abundant inflammatory 
infiltrate. Viral DNA and transcripts can be detected in spindle cells at different stages of the tumor 
development56–58. Early lesions (plaques) have no evident tumor mass. They represent well-defined 
non-ulcerated lesions with slight lymphocytic infiltrate. At this stage, the tumor contains only 10% of 
KSHV infected spindle-like cells, which line poorly structured vascular spaces and interspaced with 
extravasated red blood cells. As the tumor progresses, infiltrative tumor lesions contain than 90% 
KSHV-infected cells. Spindle-like cells form slit-like vascular spaces and bizarre vascular channels 
with evident extravasation of red blood cells and microscopic evidence of ulceration59,60. 
Spindle-like cells express markers of vascular endothelium, such as CD31, CD34, and factor VIII as 
well as markers of lymphatic endothelium including VEGFR3, LYVE1, D2-40 and markers of 
hematopoetic progenitor cells (CD117)59–65. A small proportion of spindle cells also express markers 
of dendritic cells (Factor XIII), macrophages (CD68), and α smooth muscle cells (αSMA)66,67. The 
diversity of the markers expressed sparkled the debate about the origin of the tumor and indicate 
polyclonality. It is unclear, whether the lesions descent from differentiated blood endothelial cells, 
lymphatic endothelial cells or circulating precursor cells. In the last years, a body of evidence 
indicated the ability of KSHV to transdifferentiate infected cells, which could at least partially explain 
the heterogeneity of the lesions. 
Immunohistochemistry analysis of KS lesions showed that most of the spindle cells and endothelial 
cells express LANA. Similarly, in situ hybridization studies showed that the vast majority of spindle 
cells comprising KS lesions expressed T0.7/Kaposin in a cytoplasmic distribution with a predicted 
membrane proclivity. In contrast, only small proportion of the cells (1-10%) of Kaposin-positive cells 
express PAN, as an indicator of lytic reactivation. Taken together, the studies indicate that latency is a 
predominant stage of the infection within KS lesions68.  
1.2.3 Endothelial fate reprogramming by KSHV 
Transcriptome analysis of nodular KS with more them 80% of spindle cells showed that the cells 
within the lesions more closely resemble endothelial cells than other cell types. More detailed analysis 
showed that the gene expression pattern is more similar to lymphatic endothelial cells (LECs) than to 
blood endothelial cells (BECs)69. Infection of primary BECs with KSHV leads to induction of more 
than 70% LEC-specific genes, as was shown by transcriptome and RT-qPCR analysis in both primary 
human dermal microvascular endothelial cells (HDMECs) as well as in the immortalized 
HDMECs70,71. Interestingly, infection of primary LECs leads to the upregulation of several BECs-
specific markers, bringing the phenotype closer to the one of the blood vascular endothelium69.  
1. Introduction 
17 
 
The reprogramming is likely due to virus-induced changes in cell fate-specifying transcription factors, 
such as PROX1, a master regulator of lymphatic development, and MAF. Induction of PROX1 
expression requires activation of the JAK2/STAT3 and the PI3K/Akt pathway through gp130 and can 
be reverted by pharmaceutical inhibitors of the pathway72. Expression of viral IL-6 alone, but not the 
expression of other viral genes is sufficient to mimic this process in telomerase-immortalized 
HDMECs73. Kaposin B is shown to increase cellular cytokine production by activating p38/MK2 and 
thereby increasing stability of cytokine’s mRNA74. Utilizing the same mechanism Kaposin B 
stabilizes PROX1 and induces the expression of it’s downstream targets75. The other studies indicate 
that activation of IL3 receptor alpha (IL3Rα) in BECs leads to upregulation of PROX1, whereas 
activation of Notch/Hey1 signaling  in KSHV-infected LECs leads to repression of PROX176. 
Although MAF was not previously linked to LEC/BEC differentiation, a study identified MAF as a 
transcriptional repressor, preventing expression of BEC-specific genes, thereby maintaining the 
differentiation status of LECs. Expression of KSHV-encoded miRNAs silence MAF in infected LECs 
thereby promoting expression of BEC-specific genes77.  
1.2.4 Endothelial-to-mesenchymal transition upon KSHV infection 
Endothelial-to-mesenchymal transition (EndMT) plays a vital role during cardiovascular system 
development78,79. In adults it is linked to several cardiovascular diseases, such as pulmonary 
hypertension80, vascular malformations81, myocardial infarction82, and contributes to  tumor 
environment and cancer progression.83. EndMT involves a progressive loss of endothelial markers and 
appearance of mesenchymal markers, such as αSMA, vimentin, platelet-derived growth factor 
receptor (PDGFR). These changes are accompanied by a transition from polarized to a motile and 
invasive phenotype.  
Recently it was shown that upon KSHV infection primary dermal microvascular endothelial cells 
reduce expression of endothelial-specific  markers , such as CD31, VE-Cadherin and CD31, and 
upregulate mesenchymal markers, such as Vimentin, aSMA and PDGFRβ. Transcriptome analysis of 
the cells showed upregulated expression of the genes linked to cell motility and cytoskeleton 
rearrangement. The cell undergo as well virus-induced functional changes, such as increased motility 
and loss contact inhibition84,85. Similarly, KSHV infection of lymphatic endothelial cells leads to 
increased expression of mesenchymal markers and increased invasiveness of the cells in 3D cell 
culture86. Taken together, these observations indicate that the cells acquired mesenchymal-like 
properties during infection. This transformation is induced by activation of Notch pathway and 
associated with expression of viral genes vGPCR and vFLIP86.  
KSHV-induced EndMT may help to explain the heterogeneity of the cell types found in the KS 
lesions and allows to speculate that the cells with a mesenchymal expression profile can be derived 
from KSHV-infected endothelial cells. 
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1.3 Molecular mechanisms of KSHV-induced tumorigenesis 
1.3.1 The PI3K-Akt-mTOR pathway 
Mutations in PI3K are found in one third of human cancers and 40% of breast cancers and are linked 
with cellular transformation and tumor progression. Triggering of receptor tyrosine kinases or G-
protein coupled receptors facilitate the recruitment of class I PI3Ks which phosphorylate 
phosphatidylinositol-(4,5) bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3). 
Accumulation of the latter allows phosphorylation of Akt, the main effector of the cascade which 
regulates several pathways, including inhibition of apoptosis, stimulation of mTORC1-dependent cell 
growth, and modulation of cellular metabolism. 
PI3K/Akt signalling is activated as early as 5 minutes post KSHV infection and inhibition of the 
pathway with LY294002 or wortmannin blocks virus entry. The studies indicated that PI3K 
phosphorylation is required for the activation of Rho-GTPases which play a role in endosomal 
formation and viral trafficking to the nucleus.  
Several viral proteins, including K1, vGPCR and vIL6, have been shown to induce PI3K activation to 
promote tumorigenesis and angiogenesis of the infected cells. In addition, activation of PI3K pathway 
has been shown to govern the survival advantage to the infected cells in serum starvation conditions. 
The downstream target of PI3K, mTOR is activated in lymphatic endothelial cells and its inhibition 
by rapamycin has been shown to reduce tumor progression in transplant recipients. Interestingly, 
PI3K activation is required for reactivation of the virus from latency and efficient virion production.  
In summary, these studies indicate that PI3K is one of the central pathways required for KSHV 
induced tumorigenesis as well as viral dissemination.  
1.3.2 NF-κB pathway  
Nuclear factor-κB (NF-κB) plays a central role in the regulation of diverse biological processes, 
including immune responses, development, cell proliferation and survival. Deregulated NF-κB has 
been linked to a variety of human diseases, particularly cancers. 
Similarly to PI3K, NF-κB is activated 5 minutes p.i. and persist at later time points. Although 
inhibition with small molecules does not affect viral entry, it blocks viral gene expression. The other 
studies indicate that the pathway contributes to latent maintenance of the virus, since activation of 
NF-κB blocks lytic reactivation of KSHV.  
Activated NF-κB confers a survival advantage to the infected cells and inhibition of the pathway with 
a small molecule leads to apoptosis of the infected cells as well as inhibits the expression of several 
antiapoptotic genes. Treatment of the mice with Bay11-7082, a selective pharmacologic inhibitor of 
NF-κB, prevents or delays tumor growth in murine mouse models for B-cell lymphomas.  
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1.3.3 DNA damage response and its role in virus-induced tumorigenesis 
The DNA damage response (DDR) is a cellular response to DNA damage, accidentally occurring 
either during cell division or induced by different agents. The  DDR includes the detection of DNA 
damage and finally leads to either repair of damaged DNA or cell cycle arrest and apoptosis. It 
secures genome integrity and ensures the transmission of intact genomes to daughter cells during cell 
division. The inability of the cells to adequately respond to the damage results in various clinical 
conditions, including cancer. Genome instability and a high mutation rate are considered to be 
enabling characteristics for cancer development, therefore DNA damage response genes are 
considered to be tumor suppressor genes87.  
Double-strand breaks are recognized by the MRN complex (comprising Mre11, Rad50 and NBS1), 
which mediates recruitment and activation of ATM kinase88,89. ATM, in turn, phosphorylates a 
number of downstream targets that include serine 139 of H2AX. Phosphorylated H2AX attracts 
MDC1 protein, which form the H2AX-MDC1-ATM complex flanking a damaged region, amplifying 
the DNA damage signal and initiating repair90. ssDNA, in turn, is recognized by RPA, which recruits 
ATR kinase to the damage site and induces its activation by facilitating ATR-ATRIP complex 
formation91. Phosphorylation of H2AX plays a central role in DDR.  
In addition to ATM-dependent phosphorylation at Ser139, H2AX is constitutively phosphorylated at 
Tyr142 by WSTF92. The Phosphorylation status of Tyr142, regulated by Eya phosphatases during 
DNA damage response, determines the decision for DNA repair or cell apoptosis pathways93. 
Double strand DNA damage repair is mainly carried out by two key pathways: non-homologous end 
joining and homologous recombination. Non-homologous end joining is the prevalent pathway, which 
is active during the whole cell cycle. The DNA ends are recognized by Ku70/80 heterodimer 
recruiting DNA-PK to the site of damage, which facilitates the joining of the DNA strands. 
Homologous recombination occurs in S and G2 phases of cell cycle and is orchestrated by the MRN 
complex, recruiting BRCA1 and CtIP to the site of damage94–96. 
There is accumulating evidence that in addition to their conventional role in DNA damage response 
the sensors of DNA damage also serve as cytosolic DNA sensors and trigger innate immune response 
and therefore can be viewed as a part of intrinsic intracellular defense against viruses. In particular, 
detection of viral DNA by Rad50, Mre11, IRF16, or DNA-PK induces type-1 interferon and NF-Kb 
pathways and trigger the production of downstream cytokines97–103. Several oncogenic viruses, such as 
human papilloma virus, Epstein-Barr virus, and adenovirus, induce DDR and manipulate them to their 
advantage104–107. 
KSHV triggers DDR on various stages of infection. Although ATM-dependent phosphorylation of 
H2AX determines establishment and maintenance of KSHV latency108, recognition of viral DNA by 
the MRN complex restricts KSHV replication109. KSHV evolved to manipulate DDR to its advantage 
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and the evasion of DDR by the virus is one of the molecular mechanisms of KSHV-induced 
tumorigenesis. 
1.3.4. KSHV-induced angiogenesis 
Tumor progression and metastasis rely on angiogenesis and lymphangiogenesis, since the tumor 
growth is highly dependent on the supply of oxygen, nutrients and host-derived regulators. 
Vascularization of malignant tumors involves several mechanisms, among which are directed 
capillary ingrowth (endothelial sprouting), remodeling of existing vessels, recruiting of circulating 
endothelial progenitor cells, and vasculogenic mimicry110. The letter refers to a process during which 
tumor cells acquire the ability to form vessel-like networks in three-dimensional conditions. 
Vasculogenic mimicry has been described for a various aggressive carcinomas associated with poor 
prognosis111. 
KS is an angiogenic tumor characterized by newly formed, leaky, poorly organized vessels112. KSHV 
induces angiogenesis in the infected endothelial cells by VEGF-dependent and VEGF-independent 
mechanisms49 (Fig. 1.3). VEGF has been detected in KS tissue85 as well as in plasma of KS patients86 
and its expression is induced by overexpression of several lytic proteins, such as vGPCR115, K1116, 
vIL6, and K15, in endothelial cells. The virus proteins can induce VEGF expression directly or 
activate VEGF signaling via PI3K/Akt/mTOR117, Erk and p38 signaling118,119. Although the proteins 
involved in activation of VEGF-dependent angiogenesis are expressed during lytic reactivation and 
therefore only present in minority of spindle cells, they initiate a paracrine loop inducing angiogenesis 
in the neighboring cells118.  
vGPCR and vIL6 induce Notch signaling as well as Ang2 expression via the MAPK pathway120, 
thereby leading to angiogenesis in a VEGF-independent manner. In addition, the viral K15 protein 
stimulates the phosphorylation of phospholipase Cγ1 activating VEGF downstream pathways even in 
absence of VEGF or its receptor, thereby inducing tube formation in primary VECs121. Viral latent 
proteins LANA and vFLIP contribute to angiogenesis by Ezh2-dependent regulation of ephrinB2, a 
regulator of angiogenic growth122. 
In contrast to tumorigenesis induced by other oncogenic viruses, which primarily affect cellular cell 
cycle and apoptosis, KSHV-induced tumorigenesis is characterized by altered differentiation and 
function of endothelial cells. Angiogenesis induced by KSHV in both autocrine and paracrine manner 
is the core of KS and therefore is an attractive target for novel therapeutic strategies. 
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Figure 1. 3 Schematic representation of KSHV-induced angiogenesis in endothelial cells (based on literature data). 
 
1.4 Existing treatment options and prognosis 
Up to now, there are no standard therapeutic guidelines for the management of Kaposi’s sarcoma, and 
the therapeutic strategy of each case depends on tumor location, the variant of KS, the rate of 
progression, the severity of the symptoms and the immune competence of the patient123–125.  
Therapeutic approaches for treatment of KS could be classified to local and systemic approaches. 
Local approaches include surgical excision, cryotherapy, radiotherapy, laser therapy and local 
administration of chemotherapeutic drugs123.  
Key component of treatment of HIV-associated KS is the highly active antiretroviral therapy 
(HAART), which reduces HIV viremia and reconstitutes immune system126. Some studies indicate 
that in addition to their antiretroviral activity, HIV protease inhibitors have antitumor and 
antiangiogenic properties127,128 and are able to directly inhibit KSHV thymidine kinase129, thereby 
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blocking KS growth. Although implementation of HAART reduced the risk of AIDS-KS, this tumor 
can still occur in patients with low viral load and T-cell count above 300 cell/mm3, which is above the 
level typically associated with susceptibility to opportunistic diseases130,131. Even after the 
development of HAART only 50% of patients with advanced stages of AIDS-KS achieve complete 
resolution132. 
Although early lesions of AIDS-KS are responsive to HAART, management of more advanced 
lesions requires systemic treatment123. The current first-line systemic treatment includes liposomal 
antracyclines, including daunorubicin and doxorubicin. Although the response rate to the drugs in 
combination with HAART reaches 76%, the response is 3 to 6 months delayed. The adverse effects 
include myelosuppression, opportunistic infections, stomatitis, and infusion reactions133. Second-line 
systemic drugs approved for KS include paclitaxel and etoposide. Although the response to these 
drugs reaches 71%, the adverse effects are more severe compared to first-line treatment, which makes 
them less favorable treatment options. The first- and second-line agents are expensive and not readily 
available in developing countries, where KS incidence is the highest123. When the agents are not 
available, systemic treatment includes cytotoxic therapy (bleomycin, vincristine) alone or in 
combination with HAART. This treatment has numerous adverse effects and the response range 
varies from 25-88%134,135.  
Inhibitors of viral DNA polymerase, which were initially developed for other herpesviruses, such as 
ganciclovir, cidofovir, and foscanet were shown to reduce viral load of KSHV136 and reduce the risk 
of KS in HIV-positive patients up to 62%137,138. Although the efficacy of the treatment is limited, it 
can be used to prevent new lesions123.  
Treatment of iatrogenic KS often requires reduction or elimination of immunosuppressive therapy, 
which may lead to draft rejection in 50% of the patients125. Rapamycin, a natural product from 
actinobacteria, has emerged as a therapeutic compound of benefit for transplantation-associated KS 
and was shown to have antiangiogenic effects in a murine tumor model139. Several studies also 
suggest a selective sensitivity of KSHV-infected cells to rapamycin, as its molecular target mTOR is 
crucial for the survival of KSHV-infected cells and viral pathogenesis48,140,141. This is in line with the 
observation that after renal transplantation in KSHV-infected patients the replacement of standard 
immunosuppressive drugs with rapamycin resulted in a reduction of Kaposi’s sarcoma lesions142.  
Inhibitors of angiogenesis143, VEGF144–146, tyrosine kinase50,147, and matrix metalloproteinases148 
which are related to KSHV pathogenesis, have been discussed lately and now are investigated in 
preclinical and Phase I-III clinical studies12,124. 
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1.5 Models to study KSHV infection 
The lack of a specific antiviral therapy as well as limited results that can be achieved by existing 
treatment options dictates the need for novel therapeutics. Although a set of cell-free high throughput 
screen were developed to find inhibitors of herpesviral latent proteins149,150 or proteins needed for viral 
replication151,152, the hit compounds found in those assays have to be validates in cell culture and in 
vivo models before.  
1.5.1 Cell culture systems to investigate infection of endothelial cells 
Although up to 90% of spindle cells are infected with the virus51, the cells isolated from KS lesions153–
155, as well as newly KSHV-infected human umbilical vein endothelial cells (HUVECs)156, fail to 
efficiently retain viral episomes in classic cell culture conditions. In addition, primary cells are of 
limited availability, have high batch-to-batch and donor-to-donor variation and therefore are of 
limited use for drug screening.  
Several B cell culture models were proposed as a system for screening and validation of novel 
herpesviral drugs, either targeting KSHV maintenance in latently-infected cells157 or viability of 
KSHV-infected cells158. However, there are only few cell culture systems available for investigation 
viral pathogenesis in endothelial cells and drug validation against KS. 
Studies show that telomerase-immortalized endothelial cells are susceptible for KSHV infection, 
however, similarly to the primary cells they tend to lose viral genomes upon cultivation. Intriguingly, 
upon long-term culture of the cells single clones that are able to retain viral copies, so called TIVE-
LTC, were isolated. The cells showed increased capacity to form colonies in soft agar and survival 
upon serum-deprivation, indicating tumorigenic transformation. However, similar to other adherent 
cell types8, the cells show limited potential for lytic reactivation161. Although the cell line allows 
investigation of the virus in endothelial cells and closely mimics infection of primary endothelial 
cells, several aspects of the infection differ from those described for primary cells. In particular, the 
cells fail to establish spindle-like morphology in vitro upon KSHV infection161. In addition they 
induce the expression of VEGF upon long term infection162, which is not observed upon infection of 
primary endothelial cells49,163. 
Infection of SKL cells, the uninfected cells derived from a gingival KS lesion of an HIV-negative 
renal transplant recipient, with rKSHV.219 results in a stable, latently infected cell population. In 
order to overcome the restricted reactivation rate, the cells were transduced with doxycycline-
inducible RTA transgene. The resulting cell line allows the specific viral reactivation upon addition of 
doxycycline and enables studying viral reactivation without addition of TRA or HDAC inhibitors, 
disturbing host cell biology160. Despite of the fact that SLK is generally believed to be a cell line of 
endothelial origin, recent studies show that it is indistinguishable from the human renal carcinoma cell 
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line Caki-1164.This data show that SKL is not a cell line of endothelial origin and therefore is of 
limited relevance to study KS.  
In summary, although existing cell culture models can mimic various aspects of KSHV infection, 
there is still a need for a novel cell culture model which would closely resemble the features of 
primary cells in vitro. 
1.5.2 3D cell culture systems in cancer research 
Unlike classical monolayer (2D) culture, 3D cell culture allows mirroring in vivo situation by 
incorporating physiologically relevant gradients, such as oxygen, nutrients, and metabolites165. These 
conditions are shown to be beneficial for improving the in vitro phenotype of various cell types. For 
example, global gene expression profiling showed upregulation of hepatocyte-specific markers and 
increased hepatic functions in 3D cell culture conditions of immortalized hepatocytes166. Studies 
showed that some anticancer therapeutics lose their activity in 3D cell culture and in vivo compared to 
the activity observed in a monolayer culture167. This highlights that  investigation of tumor cells in 3D 
cell culture conditions allows better understanding of tumor physiology and serves to the faithful 
preselection of novel antitumor drugs.  
Embedding of HUVEC cells, cultured on microcarrier beads, into a fibrin gel was described as a 
reliable system to study angiogenesis168. Embedding of the cells into 3D gel increases the expression 
of the genes needed for angiogenesis increased169. Moreover, 3D cell culture assay was used to study 
invasive potential of various endothelial cell lines and used a system to test novel antiangiogenic 
agents170,171. 
3D cell culture of KSHV-infected lymphatic endothelial cells showed higher expression of EndMT 
markers and therefore reflect KSHV-induced cellular transformation better than 2D cell culture86. 
Culture of KSHV-infected B cells in 3D spheroid culture showed a beneficial effect on viral 
maintenance and lytic reactivation172. This suggests that 3D cell culture conditions may better reflect 
KSHV-induced tumorigenesis and therefore represent a better system for validation of novel 
antitumor drugs.  
1.5.3 Animal models for Kaposi’s sarcoma  
The strict human-specificity of KSHV challenges the development of in vivo models. One approach 
to complement the lack of in vivo system is an investigation of genetically close herpesviruses tropic 
to other species, for example herpesvirus saimiri infecting primates and some rabbits173, rhesus 
monkey rhadinovirus174,175, and murine herpesvirus 68 (MHV68)176. Despite genetic similarity to 
KSHV and similarity in the induced B-cell pathologies177–180, the viruses fail to establish endothelial-
cell tumors and therefore are not suitable to investigate Kaposi’s sarcoma. Similarly, humanized 
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immunodeficient mice, although susceptible to KSHV and establish infection of B-cells and 
macrophages, fail to establish KS-like lesions181–183.  
Chimeric MHV68 allows studying function of individual viral genes in vivo184. By replacing G-
protein coupled receptor of MHV68 with the KSHV analog the scientists could achieve formation of 
KS-like lesions of endothelial origin in immunocompetent BALB/c mice185. 
Another approach to tackle this challenge is xenograft transplantation of the cells carrying KSHV 
genome into immunodeficient mice. Transplantation of either murine endothelial precursor cells 
(mECK36)186 or human HEK cells187 carrying a bacterial artificial chromosome (BAC) encoding the 
full length KSHV genome leads to an increased tumor potential of the cells. Similarly, KSHV 
infection of TIME cells induces tumorigenic transformation of the cells161. Both TIVE-LTC and 
mECK36 cells form KS-like lesions consisting of spindle-like cells.  
1.5.4 Conditionally immortalized human endothelial cells as a model for KSHV infection 
The limited number and patient-to patient heterogeneity of primary cells restrict their use in drug 
development. Researchers often use immortalized cell lines to overcome these limitations. The cell 
lines are usually derived from tumor tissues, upon spontaneous immortalization or upon transduction 
of immortalizing genes. However, immortalized cell often lose primary-like properties and poorly 
represent in vivo phenotype.  
It has been shown that the use of cell-type-specific immortalization regiments results in rapid 
immortalization of various cell types while preserving their properties. In particular, this approach 
allowed establishment of a series of endothelial and hepatic cell lines with primary-like phenotype 
and functionality166. However, prolonged constitutive expression of immortalizing genes can lead to a 
premalignant phenotype188. Inducible expression of immortalizing genes overcomes this limitation by 
offering strict control of cell proliferation189.  
A number of synthetic gene regulation systems were developed that allow quantitative control of gene 
expression upon administration of exogenous effector molecules. The bacteria-derived Tet promoter 
is the most commonly used inducible system190. The system consists of two elements: Tet-promoter 
and its transactivator proteins. Tet-promoter is composed of seven tet operator (TetO) DNA sequences 
from E. Coli and the minimal hCMV immediate early promoter. Transactivator proteins (rtTA) induce 
gene expression by binding to TetO sites only in presence of doxycycline while in the absence of 
doxycycline gene expression is shut off191. In addition, bidirectional tet-promoters were developed, 
which contain two minimal CMV regions flanking 7 TetO. These promoters allow simultaneous 
expression of two genes192. 
Conditional immortalization of primary HUVEC cells by transduction of the cells with lentiviral 
vector carrying immortalizing genes (SV40 large T antigen and the catalytic fragment of human 
1. Introduction 
26 
 
telomerase hTert) as well as the transcriptional transactivator rtTa driven by bidirectional tet-promoter 
resulted in growth controlled endothelial cell line, HuARLT193. The cell line preserves relevant 
phenotypic characteristics of primary endothelial cell, such as expression of majority of endothelial 
markers, uptake of macromolecules, and efficient tube formation in matrigel assay193,194. Moreover, 
HuARLT cell form a network of hCD31 positive vessels upon transplantation into 
immunocompromised mice. The formed vessel are filled with mouse erythrocytes, which indicates 
that they are functional and connected with mouse vasculature194.  
Moreover, previous studies indicate that the cell line is susceptible to infection with bacterial and viral 
pathogens targeting endothelial cells, such as human cytomegalovirus. The cell line supports the early 
and late phase of viral replication as well as the release infectious progeny virus at titers comparable 
to primary HUVECs, thus representing the full replication cycle of hCMV in endothelial cells195. The 
cells are permissive for KSHV infection. Similar to primary cells, HuARLT cells establish spindle-
like morphology and undergo a series of transcriptional changes, reflecting EndMT194. Taken 
together, these properties allow the usage of the HuARLT cell line as an alterative to primary cells to 
investigate endothelial properties upon infection both in vitro and in vivo. 
1.5.5. Recombinant KSHV.219 as a system to study latent-to-lytic switch 
The inability of endothelial cells to retain the virus can be experimentally circumvented by the use of 
a recombinant virus, carrying a selection marker. The rKSHV.219 virus carries the GFP gene under 
the control of the constitutive EF1α promoter as well as an RSV-driven puromycin acetyl transferase 
as well as the viral PAN-promoter driven RFP, enabling detection of lytically reactivated cells (Fig. 
1.4). The virus allows for selection and monitoring of the infected cells and significantly expands a 
toolbox for understanding KSHV latent-to-lytic switch196. 
 
Figure 1. 4 Schematic diagram showing the structure, the integration site of BFP/RFP/PuroR construct in rKSHV.219 
(adapted from196) and the schematic diagram of latent-to-lytic switch in KSHV.219-infected cells.  
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1.6 The aim of the study 
KS is the most common neoplasm in untreated AIDS patients and in men in sub-Saharan Africa, as 
well as one of the most common malignancies in patients after organ transplantation with limited 
treatment options and poor outcome. Although the etiological agent has been identified to be KSHV, a 
herpesvirus, the investigation of the viral pathogenesis and identification of potential antiviral 
compounds are compromised by the lack of scalable and robust in vitro models that reflect the virus-
induced changes observed in vivo. Moreover, due to the restricted host tropism of KSHV, small 
animal models have not been available so far. 
The aim of this study was to develop predictive in vitro and in vivo models to investigate the 
consequences of KSHV infection. To this end, a recently developed conditionally immortalized 
endothelial cell line should be explored upon infection with recombinant rKSHV.219. The capacity of 
the cell line to mimic KSHV-induced cell transformation and tumorigenesis should be investigated in 
standard 2D, physiologically relevant 3D cell culture conditions, as well as upon xenograft 
transplantation in vivo. 
Overall the study aimed at contributing to the understanding of molecular mechanisms of viral 
maintenance as well as the identification of novel antivirals, which can be used as targeted therapy for 
KS. 
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2. Materials and methods 
2.1. Materials 
2.1.1 Equipment 
Table 2. 1 Summary of laboratory equipment used in the study 
Name Company 
NanoDrop ND-1000 spectrophotometer  PeqLab 
TriStar² LB 942 Modular Multimode Microplate Reader Berthold Technologies 
LightCycler 480 II  Roche 
FACSCaliburTM analyzer  Becton-Dickinson 
BD™ LSR II analyzer Becton-Dickinson 
Guava EasyCount Millipore 
Zeiss LSM META Zeiss 
CO2 incubators for cell culture C200 Labotect 
Sterile work bench MaxiSafe 2020 Unity Lab Service 
Nikon TMS Inverted Microscope Nikon 
Axio Observer A1 Inverted microscope Axio 
AxioCam MRc Axio 
Axiovert 135TV Zeiss 
White light source HYP 120  
Agilent Technologies 2100 Bioanalyzer  Agilent Technologies 
Illumina HiSeq2500 Illumina 
  
2.1.2 Consumables 
 
Name Company Catalogue Number 
AggreWell™400  Stemcell Technologies 27945 
Cell culture plates  Nunc Multidish/Nunclon  
Falcon tubes (15, 50 ml) Greiner bio-one 188271, 227261 
SafeSeal tubes (1,5 ml) Sarstedt 72.706 
LightCycler 480 Multiwell Plates 96 Roche 04 729 692 001 
Cell strainer EasyStrainer 40 µm Greiner bio-one 542040 
Syringes, 1ml Omnifix®, Braun 9161406V 
Disposable hypodermic needle 
Sterican 100, 20G 
Braun 4657519 
  
Table 2. 2 The list of consumables 
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2.1.3 Chemicals 
Table 2. 3 Summary of the chemicals and kits used in the study 
Compounds Company Catalogue number 
12-O-Tetradecanoylphorbol 
13-acetate (TPA) 
Sigma P1585-1MG 
5-dodecanoylaminofluorescein 
di-beta-D-galactopyranoside 
(C12FDG) 
Molecular probes D2893 
5-fluoro-2’-deoxyuridine 
(FuDR) 
Sigma F0503 
Agarose LE Biozym 840004 
Albumin from bovine serum 
(BSA) 
Sigma A3294-100G 
AlexaFluor™ 488 acetylated 
low dencity Lipoprotein From 
Human Plasma 
Invitrogen  L2338 
Bafilomycin A1 from 
Streptomyces griceus 
Sigma B1793-10UG 
BAY11-7085 Cayman Chemical 14795 
DAPT Cayman Chemical 13197 
Doxycycline hyclate Biochemica 24390-14-5 
Dynabeads® mRNA 
DIRECT™ Micro Purification 
Kit  
Thermo Fisher 61006 
Fetal Bovine Serum (FCS) Sigma F7524 
FGF  PeproTech 100-18B-250 
Fibrin Calbiochem 341576 
FK506 Abcam Ab120223 
FluoroshieldTM  Sigma F6057-20ML 
Gelatin Sigma G1393-100ML 
Glycarrhizic acid (GA) abcam Ab143127 
Guava ViaCount® EMD Millipore 4000-0040 
GW5074 Cayman Chemical 10010368 
IsoFlo (Isofluran) Zoetis TU061220 
Ku55933 Cayman Chemical 16336 
LY294002 Cayman Chemical 70920 
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Manumycin BioViotica BVT-91-M001 
Matrigel high protein (HC), 
growth factor reduced 
Becton Dickinson 354263 
Matrigel, growth factor 
reduced 
Becton Dickinson 354230 
Methylcellulose  Sigma M0512 
Mirin Cayman Chemical 13208 
MLS000544460 Calbiochem 5.31085.0001 
Nu7441 Cayman Chemical 14881 
Phosphonoformic acid 
trisodium salt hexahydrate 
(PhA) 
MP biomedicals, LLC 195426 
Proteinase K Qiagen 19133 
Puromycin dihydrochloride 
from Streptomyces alboniger 
Sigma P7255-1G 
Rapamycin Cayman Chemical 13343 
Reverse-Aid First Strand 
cDNA Synthesis Kit 
Fisher Scientific K1622 
RNAeasy mini kit  Quiagen 74106 
Saponin Quillaja sp. Sigma S4521 
ScriptSeq v2 RNA-Seq Library 
Preparation Kit  
Epicentre SSV21106 
SsoFast™ EvaGreen® 
Supermix 
Biorad 1725204 
Thrombin Merck Millipore 605190-100U 
Triton® X-100 molecular 
biology grade 
Serva 39795.02 
TruSeq SBS Kit v3-HS Illumina FC-401-3002 
U126 Calbiochem 662005-1MG 
VEGF Randox RCPG246 
WST cell counting kit 8 Sigma 96992-500TESTS-F 
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2.1.4 Media and buffers 
Table 2. 4 Media and buffers used in the study 
Name Company Catalogue number 
Endothelial growth media Lonza CC-3124 
Endothelial Cell Growth 
Medium (Ready-to-use) 
Promocel C-22010 
Hanks’ Balanced Salt Solution Tebu-Bio 088HBSS-500 
 
Table 2. 5 Buffer formulations 
Buffer Composition  
PBS NaCl 140 mM 
KCl 27 mM 
Na2HPO4 7,2 mM 
pH 6.8-7.0 
FACS buffer PBS 
2% FCS 
Modified Bradley’s Buffer Tris 1.21 g/l 
NaCl 0.58 g/l 
EDTA 2mM 
SDS 0,5% 
pH 7,5 
Proteinase K 30 mAU/ml  
2.1.5 Antibodies 
Table 2. 6 List of antibodies and applications. IF – immunofluorescence, IHC – immunohistochemistry. 
Epitope Conjugate Dilution Host Company  Catalogue Nr Application 
LANA Unconj. 1:100 Mouse Leica NCL-HHV8-
LNA 
IF 
1:30 IHC 
CD141 Unconj. 1:40 Mouse Serotech MCA641T IHC 
CD34 Unconj 1:100 Mouse BD Pharmingen 555746 FACS, IHC 
GFP HR 1:10 Rabbit Santa Cruz 
Biotechnology  
sc-8334 IHC 
Vimentin Unconj. 1:100 Mouse Dako M0725 IHC, FACS, 
IF 
Ki67 Unconj. 1:100 Rabbit NeoMarkers RM-9106-PCS IF 
CD31 Unconj. 1:100 Mouse BD Pharmingen 555444 IF 
CD146  Unconj. 1:100 Mouse BioLegend 134701 FACS 
CD 144 (VE-
Cadherin) 
Unconj 1:100 Mouse BioLegend 348501 FACS, IF 
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ZO-1 Unconj 1:100 Mouse BD Transduction 
Laboratories 
610966 IF 
mouse Cy3 1:1000 Goat Dianova 115-165-068 IF, FACS 
mouse APC 1:1000 Goat Biolegend 405308 FACS 
rabbit Cy3 1:200 Goat Dianova 111-166-045 IF, FACS 
2.1.6 Primers 
Table 2. 7 List of primers used. All the primers used in the assay were synthesized by Eurofins genomics. 
Name Sequence Number 
ACTB Forward TCACCCACACTGTGCCCATCTACGA P5440 
Reverse CAGCGGAACCGCTCATTGCCAATGG P5441 
Akt Forward TGAAGGTGCCATCATTCTTG  P5422 
Reverse ATGAGCGACGTGGCTATTGT P5423 
C1ORF43 Forward AAGGAGCTGGGGCTCATACT P5629 
Reverse GTGAATGTCGTGCTGGTGAT P5630 
CD31 Forward GGAAACCATGCAATGAAACCAA P5464 
Reverse GTCCTTCTTTCCTAGATCTTTGTGA P5465 
cRaf Forward TGAATCCAAAACCATTGCTG P5426 
Reverse GAACGACAGGACGTTGGG  P5427 
Eya1 Forward TCCAACAGACCATACCCACA P5589 
Reverse AATCCTGTCTGTCCAGGTGA P5590 
Eya2 Forward ACACAATGGACCTTCCACAC P5591 
Reverse TGGTCACAATCCTTCCCGTA P5592 
Eya3 Forward TACTTCCGGTTCCTAGCGAT P5593 
Reverse GTAAAAGCCCCACAACAGGA P5594 
Eya4 Forward GTTTAGGAGGTGCTTTCCCC P5595 
Reverse TTGCTGCCTGTTCTTCTTCT P5596 
GFP Forward AGCTGCCCGTGCCCTGGCCC P3429 
Reverse TGTACTCCAGCTTGTGCCCC P3430 
H2AX Forward ACAACAAGAAGACGCGAATC P5597 
Reverse CTCTTAGTACTCCTGGGAGGC P5598 
Hes1 Forward TACTTCCCCAGCACACTTGG P5448 
Reverse CGGACATTCTGGAAATGACA P5449 
Hey1 Forward CGAAATCCCAAACTCCGATA P5450 
Reverse TGGATCACCTGAAAATGCTG P5451 
Jag1 Forward GTCCATGCAGAACGTGAACG P5446 
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Reverse GCGGGACTGATACTCCTTGA P5447 
Jak2 Forward CCATTCCCATGCAGAGTCTT P5430 
Reverse CAGGCAACAGGAACAAGATG P5431 
Kaposin Forward GGATAGAGGCTTAACGGTGTTT P5609 
Reverse CAGACAAACGAGTGGTGGTATC P5610 
k-bZIP Forward GGTCTGTGAAACGGTCATTGA P5601 
Reverse TCTATGTAGTCGCCTCTTGGA P5602 
LANA Forward TTGGATCTCGTCTTCCATCC P5442 
Reverse ACCAGACGATGACCCACAAC P5443 
MEK Forward GGGAGCTCTCTGAGGATGG P5428 
Reverse CGGAGGATCGACCTCAAC P5429 
MMP2 Forward TCTCCTGACATTGACCTTGGC P5621 
Reverse CAAGGTGCTGGCTGAGTAGATC P5622 
MMP10 Forward GCATCTTGCATTCCTTGTGCT P5623 
Reverse TTTTGCTGCCCCACTCAGA P5624 
mTOR Forward TCCGGCTGCTGTAGCTTATTA P5424 
Reverse CGAGCATATGCCAAAGCACT  P5425 
Notch1 Forward GAGGCGTGGCAGACTATGC P5444 
Reverse CTTGTACTCCGTCAGCGTGA P5445 
ORF33 Forward CGACCTGACCAATTGCACTA P5615 
Reverse ATGTTAGATAGACCCGGCGA P5616 
ORF45 Forward  GCGGCTTAAGTTTGGTTGTC P5613 
Reverse ACATCGGACTCTGATAGCGA P5614 
ORF50 Forward CACAAAAATGGCGCAAGATGA P5603 
Reverse TGGTAGAGTTGGGCCTTCAGTT P5604 
PAN Forward TGCATTGGATTCAATCTCCAGGCCA P5599 
Reverse GTAGTGCACCACTGTTCTGATACAC P5600 
PI3K Forward TGCTATGCCTGCTCTGTAGTGGT  P5420 
Reverse GTGTGACATTGAGGGAGTCGTTG P5421 
PROX1 Forward ATCCTAATTTATTTGATGAAGGTG P5472 
Reverse TGCACATACATTCAGTTTAAGAGG P5473 
RPS6KB1 Forward TTCATATGGTCCAACTCCCC P5438 
Reverse AGGACATGGCAGGAGTGTTT P5439 
Tie-1 Forward CACGACCATGACGGCGAAT P5625 
Reverse CGGCAGCCTGATATGCCTG P5626 
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Tie-2 Forward AGTAGDCATATTCACCATCAACCG P5627 
Reverse TGCCAAGCCTCATAGTGATTAACG P5628 
TLR2 Forward CCACTGACAAGTTTCAGGCA P5434 
Reverse TCATTTGGCATCATTGGAAA P5435 
TLR4 Forward AACTCTGGATGGGGTTTCCT P5436 
Reverse GTGAGACCAGAAAGCTGGGA  P5437 
vCyclin Forward AGCTGCGCCACGAAGCAGTCA P5607 
Reverse CAGGTTCTCCCATCGACGA P5608 
VE-cadherin Forward TCCTCTGCATCCTCACTATCACA P5619 
Reverse GTAAGTGACCAACTGCTCGTGAAT P5620 
VEGFR1 Forward TGGGACAGTAGAAAGGGCTT P5466 
Reverse GGTCCACTCCTTACACGACAA P5467 
VEGFR2 Forward CATCACATCCACTGGTATTGG P5468 
Reverse GCCAAGCTTGTACCATGTGAG P5469 
VEGFR3 Forward CCCACGCAGACATCAAGACG P5470 
Reverse TCGAGAACTCCACGATCACC P5471 
vFLIP Forward GCGGGCACAATGAGTTATTT  P5611 
Reverse GGCGATAGTGTTGGGAGTGT P5612 
vIL-6 Forward AAAACACGCACCGCTTGACCTG P5605 
Reverse TTCACTGCTGGTATCTGGAACG P5606 
vIRF2 Forward CGGAATGGCTCACGGACTTTAT P5617 
Reverse AGACATCCTTCACATCCCTTGT P5618 
2.2 Methods 
2.2.1 Cell culture 
Human conditionally immortalized endothelial cells HuARLTs were described before193. rKSHV-
HuARLT cells194 were derived upon infection of HuARLTs with recombinant KSHV.219 carrying the 
constitutively expressed GFP and puromycin selection genes as well as RFP under control of a viral 
lytic promoter196.  
The cells were cultivated on plates coated with 0.5% gelatin in endothelial growth medium in a 
humidified normoxic atmosphere with 5% CO2 in the presence of 2 µg/ml doxycycline. Maintenance 
cultures of rKSHV-HuARLT cells additionally contained 5 µg/ml puromycin, while all the 
experiments were performed in the absence of the selection drug.  
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When needed, the cells were counted using Guava ViaCount staining solution according to the 
manufacturers protocol. In brief, the cells were diluted 1:10 in the staining solution, incubated for 5 
minutes at rom temperature prior to evaluation of cell viability and cell counting on Guava analyzer. 
2.2.2 Cell viability and determination of drug concentrations 
To assess cell viability upon treatment with standard drugs, rKSHV-HuARLT cells and HuARLT 
cells were seeded in 96-well plates (5000 cells/well) and incubated with the compounds in the 
indicated concentrations. The maximal concentration of solvent did not exceed 0.5% of the total 
volume. Cell viability was measured using the WST-based Cell Counting Kit 8 according to the 
manufacturer’s instructions. In brief, cells were incubated with 100 µl of fresh media and 10 µl of the 
WST-8 solution at 37° C for 2-4 hours followed by absorbance measurement at 450 nm using TriStar² 
LB 942 Modular Multimode Microplate Reader. To calculate cell viability, the background values 
were subtracted and the data was normalized to DMSO-treated control values.  
2.2.3 Natural compound library and selection of the drug concentration 
The natural compounds used in this study have been compiled at the Helmholtz Center for Infection 
Research and the Helmholtz Institute for Pharmaceutical Research Saarland in a ready-to-screen 
library that is available for screenings to evaluate their utility in various biological assays. The 
chemical synthesis of pretubulysin D was described before197. For assays on endothelial cells only 
derivatives from active compound classes were selected that are feasible for in vivo studies due to 
availability and overall better characterization in terms of biological effects in other in vitro and in 
vivo experiments.  
To determine the appropriate concentration for the drugs, at least 4 concentrations per compound with 
3 replicates were tested for cell viability. The drug concentration that resulted in at least 80% viability 
is summarized in Table 2.7 and was used for further experiments.  
Compound Concentration  
Glycyrrhinic acid (GA) 25 µM 
Phosphonoformic acid (PhA) 100 µM 
Carolacton 20 nM 
Chondramid B 25 nM 
Chondramid C 25 nM 
Disorazol A5 10 nM 
Eliamid 50 nM 
Epothilon B 1 nM 
Epothilon E 20 nM 
Hyaboron 50 nM 
Icumazol B2 20 nM 
Myxalamid PI 1 µM 
Table 2. 8 Final concentration of the novel compounds used in the study. 
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Myxochelin A 20 nM 
Myxothiazol A 1 µM 
Pellasoren A 1 nM 
Phenoxan 500 nM 
Pretubulysin D 1 nM 
Saframycin Mx 1 20 nM 
Soraphen A 500 nM 
Soraphen B 500 nM 
Stigmatellin A 2,5 µM 
Stigmatellin F 20 nM 
Stigmatellin G 20 nM 
Thiangazol A 500 nM 
Trichangion 4 µM 
Tubulysin A 25 nM 
Tubulysin G 1 nM 
Tubulysin X 25 nM 
Tubulysin Y 10 nM 
2.2.4 Spheroid production  
4000 rKSHV-HuARLT cells per well were seeded on a 0.5% agarose-coated 96-well plate and 
cultivated at 37° C in a humidified normoxic atmosphere with 5% CO2. After 24- or 48 hours, the 
formed aggregates (spheroids) were harvested and embedded either in a fibrin gel (for spheroid 
sprouting assays) or in a Matrigel matrix (for copy number analysis). 
2.2.5 Viral copy number analysis 
2D cultures: rKSHV-HuARLT cells were seeded on a 12-well plate (1105 cell/well) and treated with 
the test compounds in absence of doxycycline and puromycin for 14 days.  
3D cultures: for every well 6 to 8 spheroids were mixed with 0.7 mg/ml fibrin, 0.4% methylcellulose 
and 0.5 U/ml thrombin in EGM medium. Growth-factor reduced Matrigel was added to the spheroid 
mixture in a ratio of 1:1. 100 µl of the gels were cast onto a 96-well plate and allowed to solidify for 
30 min at 37° C. 100 µl of EGM supplemented with selected compounds was added on top of the 
gels.  
After 14 days of treatment, DNA was isolated from cells cultured under 2D or 3D culture according to 
a protocol described before198. Briefly, the cells were lysed using modified Bradley’s buffer with 
Proteinase K at 55° C overnight. Cellular DNA was precipitated in 75 mM sodium acetate in 96% 
ethanol solution. The pellet was washed with 70% ethanol, dried and suspended in nuclease-free 
water. qPCR was performed at 58° C annealing temperature using SsoFast™ EvaGreen® Supermix  
in a LightCycler 480 II. The data were analyzed using Light Cycler 480 software 1.5. Viral DNA was 
detected using LANA specific primers and normalized to cellular DNA detected by the ACTB 
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specific primer pair. The number of viral copies per cell was extrapolated using a modified ΔCp 
method, taking into account that the cellular genome harbors 2 copies of the ACTB gene: 
𝑉𝑖𝑟𝑎𝑙 𝑐𝑜𝑝𝑦 𝑛𝑢𝑚𝑏𝑒𝑟/𝑐𝑒𝑙𝑙 = 2 ∗ 2𝐶𝑝𝐿𝐴𝑁𝐴−𝐶𝑝𝐴𝐶𝑇𝐵  
2.2.6 Spheroid sprouting assay 
Spheroids from rKSHV-HuARLT cells were embedded in fibrin gels according to a protocol 
described in86. 6-8 spheroids were mixed with in fibrin solution (3 mg/ml) supplemented with 2 U/ml 
thrombin and 0.25% methyl cellulose in Hanks’ Balanced Salt Solution. The mixtures were cast onto 
a 96-well plate and allowed to solidify for 30 minutes at 37° C. The respective compounds were 
added in EGM media using the concentrations listed in Table 1 and incubated for 5 days. 
Quantification of spheroid sprouting was performed from fluorescence microscopy images using 
ImageJ software171. To this end, the area covered by sprouts at the representative focus plane was 
measured and normalized against the spheroid’s core area (sprouting index).  
𝑆𝑝𝑟𝑜𝑢𝑡𝑖𝑛𝑔 𝑖𝑛𝑑𝑒𝑥 =
𝑇𝑜𝑡𝑎𝑙 𝑎𝑟𝑒𝑎 − 𝑐𝑜𝑟𝑒 𝑎𝑟𝑒𝑎
𝐶𝑜𝑟𝑒 𝑎𝑟𝑒𝑎
 
 
Figure 2. 1 Quantification of in vitro sprouting (representative pictures).  
The total area and the core area was measured using ImageJ software and the sprouting index was calculated as indicated 
for one representative section per spheroid. 
2.2.7 Relative gene expression (RT-qPCR) 
Total RNA was isolated from 5105 rKSHV-HuARLT cells using RNAeasy mini kit  according to the 
manufacturer’s instructions and measured with the ND-1000 spectrophotometer. cDNA was 
synthetized from 500 ng of RNA using Reverse-Aid First Strand cDNA Synthesis Kit according to the 
manufacturer’s instructions. Quantitative PCR was performed as described above using the primers 
specified above. Relative expression of genes in relation to cellular ACTB or C1ORF43 was 
calculated using the standard ΔCp method. 
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2.2.8 Flow cytometry 
In order to analyze GFP expression, rKSHV-HuARLT or HuARLT cells were washed and detached 
with trypsin/EDTA and resuspended in PBS supplemented with 2% FCS. Flow cytometric analysis 
was performed on a FACSCaliburTM analyzer. Non-infected cells were used as a negative control. The 
data were processed with FlowJo v10 software. 
For analysis of surface markers of endothelial cells, the cells were harvested ad described above 
followed by fixation in 4% formaldehyde for 20 minutes. For intracellular staining (Vimentin) the 
cells were permeabilized by 0,2% of triton X-100. The cells were incubated with primary antibodies 
for 30 minutes at 4° C followed by washing with PBS and incubation with secondary antibodies for 
30 minutes at 4° C at the dilutions indicated above. The samples were analyzed with BD™ LSRII 
analyzer. The cells treated with secondary antibodies only were used as a control.  
2.2.9 Uptake of acetylated low-density lipoproteins 
For the uptake of acetylated low-density lipoproteins (AcLDL) the cells were cultivated for 4 hours 
with 10 mg/ml AlexaFluor™ 488 labeled AcLDL at 37° C. Following the incubation the cells were 
trypsinized, resuspended in FACS buffer and analyzed by flow cytometry. 
2.2.10 Detection of senescence-associated beta-galactosidase activity 
Fluorescence based assay to detect senescence-associated beta-galactosidase activity were performed 
according to previously published protocol199. In brief, the cells were pretreated with 100 nM 
bafilomycin A1 for 1 hour followed by addition of C12FDG to the final concentration of 33 µM. After 
2 hours of incubation the cells were trypsinized and suspended in ice-cold FACS buffer followed by 
FACS analysis.  
2.2.11 Matrigel tube formation assay 
Matrigel tube formation assay was performed according to previously published protocols200,201. 
Briefly, 24-well plates were coated with Matrigel for 30 min at 37° C. 1.2x105 cells were seeded per 
well and cultivated for 16 h in EGM medium in presence or absence of doxycycline. The formation of 
tube-like structure was evaluated by microscopic analysis using Angiogenesis Analyser plug-in for 
ImageJ202. 
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2.2.12 Gene expression profiling by gene arrays 
In this study, the ‘Whole Human Genome OligoMicroarray’ (AMADID 014850, Agilent 
Technologies) was used containing 45015 oligonucleotide probes covering the entire human 
transcriptome. Total RNA utilized for microarray experiments was prepared with the RNeasy Mini 
Kit. The microarray experimentswere realized as biological duplicates. Quality and integrity of the 
total RNA was controlled on an AgilentTechnologies 2100 Bioanalyzer. 50 ng of total RNA were 
applied for Cy3-labeling reaction using the one color Quick Amp Labeling protocol (Agilent 
Technologies). Labeled cRNA was hybridized to Agilent’s human 4 9 44k V1 microarrays for 16 h at 
68° C and scanned using the Agilent DNA Microarray Scanner G2505C US84903606. Expression 
valueswere calculated by the software package Feature Extraction 10.5.1.1 (Agilent Technologies). 
Statistical analysis of the expression datawas performed using theGene SpringGX Software V.12 
(Agilent Technologies). Entities that showed technical impairments were excluded from final 
analysis.  
The raw data were imported into R, log2-transformed according to the recommended default 
procedure and interarray quantile normalized. The genes were considered to be differentially 
regulated if expression change is higher than 2 fold and adjusted p-value is less than 0.01 as 
determined by ANOVA test. Canonical pathways enriched in Gene Ontology analysis by 
differentially expressed genes was visualized by ClusterProfiler203 tool. Network visualization of 
selected enriched biological processes was achieved by EnrichMap204 tool, using Kamada-Kawai 
layout. 
2.2.13 Gene expression profiling by RNA-Seq 
 Quality and integrity of total RNA was controlled on Agilent Technologies 2100 Bioanalyzer. The 
RNA sequencing library was generated from 500ng total RNA using Dynabeads® mRNA DIRECT™ 
Micro Purification Kit for mRNA purification followed by ScriptSeq v2 RNA-Seq Library 
Preparation Kit according to manufacture´s protocols. The libraries were sequenced on Illumina 
HiSeq2500  using TruSeq SBS Kit v3-HS (50 cycles, single ended run) with an average of 3 x107 
reads per RNA sample. Each FASTQ file gets a quality report generated by FASTQC tool205. Before 
alignment to reference genome each sequence in the raw FASTQ files were trimmed on base call 
quality and sequencing adapter contamination using Trim Galore!206 wrapper tool. Reads shorter than 
20 bp were removed from FASTQ file. Trimmed reads were aligned to the reference genome using 
open source short read aligner STAR207 with settings according to log file. Feature counts208 were 
determined using R package Rsubread. Only genes showing counts greater 5 at least two times across 
all samples were considered for further analysis (data cleansing). Gene annotation was done by R 
package bioMaRt209. Before starting the statistical analysis steps,  expression data was log2 transform 
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and normalized according to 50th percentile (quartile normalization using edgeR210).  Differential 
gene expression was calculated by R package edgeR.  Functional analysis was performed by R 
package clusterProfiler203.  
2.2.14 B cell based high throughput screening of natural compound library against KSHV 
lytic replication 
The screening of the natural compounds library was done by T. Schultz and G.Beauclair. In brief, 
Brk.219, a BJAB cell line stably infected with rKSHV.219211,212 was used to screen a library of 260 
natural compounds. Brk.219 cells were seeded into round bottom 96 well plates at a density of 105 
cells per well in 100 l RPMI medium. Compounds were added at a final concentration of 10 µM and 
the viral lytic cycle induced by the addition of an antibody to human IgM on the BJAB cell surface as 
described211. Forty-eight hours later the supernatant of individual wells was collected and used to 
infect HEK293 cells. After a further 48 hours the number of GFP positive HEK293 cells was 
quantified by a Biotek fluorescence reader. The viability of the treated Brk.219 cells was determined 
by MTT assay.  
2.2.15 Immunofluorescence microscopy 
rKSHV-HuARLT cells were plated on 0.5% gelatin-coated cover glass slips and fixed for 20 min with 
4% formaldehyde in PBS followed by permeabilization with 0.5% Triton X-100 in PBS for 10 min. 
Blocking of the samples was done in PBS supplemented with 2% BSA for 1h. The coverslips were 
stained with primary antibodies in PBS with 0.1% saponin Quillaja sp. at 4°C overnight, diluted as 
inducated above. Staining with secondary antibodies was performed in in PBS with 0.1% saponin at 
RT for 1h. Coverslips were mounted on glass slides with FluoroshieldTM containing DAPI and 
incubated at room temperature overnight. Images were acquired using a Zeiss LSM META confocal 
laser scanning microscope. Brightness and contrast were adjusted using ImageJ software. 
2.2.16 Mouse experiments  
rKSHV-HuARLT cells were transplanted to mice as described before194. In brief, 1.2106 cells were 
seeded into each well of AggreWell™400, centrifuged for 3 minutes at 100 g and cultivated for 3 
days at 37° C. 400 spheroids were used for each matrigel implant containing 0.2% methyl cellulose, 3 
mg/ml fibrinogen in EGM media supplemented with 10 µg/ml FGF, 0.5 µg/ml VEGF, 1 U/l thrombin 
and 300 µl of Matrigel HC, growth factor reduced. The mixture was injected subcutaneously to Rag2-
/-γc-/- mice.  
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For singe cell analysis, the plugs were isolated 4 weeks after transplantation, cut into smaller pieces, 
and digested with Collagenase H (1 mg/ml) in PBS at 37° C for 1 hour. Digested cell suspension was 
filtrated via cell strainer to eliminate cell clumps. The flow-through was centrifuged down, the cells 
were resuspended in FACS buffer and analyzes by FACS as described above. 
Starting from day 1 after implantation, the mice were treated with the drugs according to the route, 
dose and regime adapted from previous studies. Animal experiments were performed in accordance to 
the local animal law. 
Table 2. 9 Dosage, administration route and regime of in vivo application of selected compounds 
Compound Route Dose, 
[mg/kg] 
Frequency Solvent Volume, [µL] Reference 
Chondramide B i.v. 0,5 Once a 
week 
PBS+5% 
DMSO 
100 213 
Pretubulysin D i.v. 1 Once a 
week 
PBS+5% 
DMSO 
100 214,215 
Epothilon B i.v. 2,5 Once a 
week 
PBS+5% 
DMSO 
100 216,217 
Soraphen A oral 50 3x/week Water 100 218 
FK506 i.p. 2 3x/week PBS+5% 
EtOH 
100 219 
Rapamycin i.p. 1 3x/week PBS+5% 
EtOH 
100 219 
Phosphonoformic 
acid 
i.p. 200 3x/week PBS 100 220 
2.2.17 Immunohistological stainings 
After 4 weeks of treatment, Matrigel implants were extracted and fixed with 4% formalin, embedded 
in paraffine, sectioned and stained with hematoxylin-eosin or with immunohistochemistry staining. 
The antibodies and their dilutions are listed above. Diameters of the lesions were measured on 
histological sections, stained for human vimentin. Human endothelial cells were marked applying in 
situ hybridization technique (ALU). The ALU probe was purchased from Ventana/Roche Diagnostics 
GmbH applying Ventana ISH detection kit.  
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3. Results 
3.1. Evaluation of conditionally immortalized HuARLT cells as a system to 
investigate KSHV infection 
The investigation of KSHV pathogenesis and the identification of potential antiviral compounds are 
compromised by the lack of scalable and robust in vitro cell culture models that reflect the virus-
induced changes observed in patients. Recently, conditionally immortalized human endothelial cells 
(HuARLT) were developed, which preserve the properties of primary endothelial cells193. It has been 
shown that the cells express key markers of blood endoderm and maintain many endothelial functions, 
such as tube formation, barrier functions, eNOS activity and uptake of AcLDL193,194. Moreover, the 
cell line gives rise to functional blood vessels when transplanted into immunocompromised mice194. 
To evaluate this cell line as a model for KSHV infection, the capacity of the cell line to reflect the 
changes, observed upon KSHV infection of primary cells was investigated. 
3.1.1. HuARLT cells are tightly growth controlled 
HuARLT cells carry immortalizing genes and rtTa driven by bidirectional tet-promoter193 (Fig. 3.1A). 
This construct allows the expression of immortalizing genes, and, as a result, cell proliferation only on 
presence of doxycycline. In order to confirm that the cells are tightly growth-controlled even after 
prolonged passaging, 1x104 cells were seeded in 12-well plates and cell numbers were measured upon 
cultivation with or without doxycycline for 13 days. Cell samples were counted every 2-3 days. The 
result shows that the cell number increases in presence of doxycycline, whereas it remains constant 
when doxycycline is withdrawn, thus confirming doxycycline-dependent growth control (Fig. 3.1B). 
Cell proliferation slowed down after day 8 of the culture, likely due to contact inhibition of the cell 
growth, since the cells were maintained within the same cell culture dish for the whole experiment. Of 
note, non-proliferating cells show less than two fold increase in senescence-associated β-galactosidase 
staining, indicating marginal signs of senescence within the first 9 days. (Fig. 3.1E). 
In order to evaluate the frequency of proliferating cells in the culture, expression of Ki-67, the cellular 
proliferation marker, was evaluated by immunofluorescence staining of the cells cultured in presence 
or absence of doxycycline for 3 days (Fig 3.1C and D). The percentage of Ki-67 positive cells was 
quantified as the number of Ki-67 positive cells related to the number of nuclei visualized by DAPI 
staining per field of view. As a result, 89,40±1,16% of Ki-67 positive cells were observed in 
doxycycline-treated samples, whereas only 0,96±0,06% of the cells were Ki-67 positive upon 
withdrawal of doxycycline. Taken together, the data confirm that the cells are tightly growth-
controlled.  
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3.1.2 Conditionally immortalized endothelial cells preserve properties of primary cells 
It has been shown before that conditionally immortalized human endothelial cells preserve endothelial 
functions, as measured by AcLDL uptake, and express of endothelial specific markers CD31, CD105, 
CD102 to similar levels as primary endothelial cells193. In order to confirm that the cells kept these 
properties upon prolonged cultivation, total RNA was isolated from primary HUVEC cells and 
HuARLT cells on passage 60 and the expression levels of several endothelial-specific markers were 
measured by RT-qPCR. The result showed that the expression levels of VEGFR1, Tie-1, CD31 and 
VE-Cadherin were moderately reduced in HuARLT cells compared to the levels in primary cells. 
Expression of VEGFR2 and Tie-2 could be detected in conditionally immortalized cells, but it was 
markedly reduced in comparison with HUVECs. Interestingly, the expression levels on VEGFR2, 
 
Figure 3. 1 HuARLT cells are tightly growth controlled.  
A) a scheme of the immortalization cassette (adapted from193). Transactivator protein (rtTA) binds to the operator sequences 
within the tet promoter and initiates transcription of the immortalizing genes only in presence of doxycycline (Dox). 
Bidirectional tet promoter allows co-expression of rtTa and immortalizing genes. B) Cell numbers of HuARLT cells upon 
cultivation with and without doxycycline. 104 cells were cultured on gelatin-coated plates with or without doxycycline, 
respectively. Cell numbers were counted every 2-3 days, the mean of 4 replicates is shown per time point. C) Representative 
images of immunofluorescence staining for Ki-67. HuARLT cells were cultured in presence or absence of doxycycline for 3 
days followed by fixation and the staining with an anti-Ki-67 antibody. The primary antibody was detected by Cy3 
conjugated anti-IgG, scale bar 100 µm. D) Quantification of relative Ki-67/DAPI ratio shown in C, 3 biological replicates 
were analyzed with 3 fields if view per replicate. E) HuARLT cells were stained for senescence-associated β-galactosidase 
using a 5-dodecanoylaminofluorescein di-beta-D-galactopyranoside (C12FDG), a fluorogenic substrate for β-galactosidase 
activity. .The expression level was quantified by flow cytometry at indicated days. Shown is the mean fluorescence intensity 
(MFI) of HuARLT cells cultured either in absence or in presence of doxycycline for 13 days. The data based on 3 replicates 
per condition at each time point. 
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CD31 and VE-Cadherin was significantly lower in proliferating HuARLT cells, compared to non-
proliferating cells (Fig. 3.2.A) indicating that non-proliferating HuARLT cells closer resemble 
primary endothelial cells.  
Transcriptome analysis confirmed that non-proliferating HuARLT cells express more endothelial-
specific genes than proliferating cells, indicating that proliferation status influences endothelial 
phenotype194. In order to verify that this observation reflects intrinsic properties of endothelial cells 
rather than a cell culture artifact, HUVEC cells were treated with 5-Fluoro-2’-deoxyuridine (FuDR), a 
small molecule inhibiting DNA synthesis and thereby reducing cell proliferation. After 7 days of 
cultivation, the total RNA was isolated and the expression levels of selected proliferation-sensitive 
genes (as identified by transcriptome analysis) was measured by RT-qPCR. HuARLT cells cultured 
either in absence or in presence of doxycycline for 7 days were used as a control. The analysis shows 
that reduction of cell proliferation increases expression of MMP2, MMP10 and VE-Cadherin 
expression in both primary HUVECs and conditionally immortalized HuARLT cells (Fig. 3.2 B and 
C). 
The ability to uptake of acetylated low density lipoproteins is regarded as a specific feature of 
endothelial cell and macrophages. To see weather proliferation can affect this function, the uptake of 
fluorescently labeled AcLDL was measured by FACS-analysis of HUVECs treated with FuDR for 7 
days and HuARLT cells cultured either in presence or in absence of doxycycline. The results show 
that both the primary and the immortalized cells reduce the uptake of AcLDL upon proliferation (Fig 
3.2 D and E).  
Taken together, the data confirmed that HuARLT cells maintained the endothelial properties upon 
prolonged cultivation and showed that the proliferation specific changes in the endothelial phenotype 
reflect the changes in primary cells.  
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3.1.3 HuARLT cells are susceptible for KSHV infection 
To validate HuARLT cells as a cell culture model for KSHV infection, the cells were infected with 
rKSHV.219196 at MOI 10. The virus constitutively expresses the GFP and puromycin acetyl 
transferase genes, which allows for selection and monitoring of the infected cells. Infected cells show 
punctuated localization of the latency associated nuclear antigen LANA in the nuclei indicating the 
association of viral episomes with the cellular chromosomes (Fig. 3.3A). If cultivated under selection 
pressure, the rKSHV.219-infected HuARLT cells (rKSHV-HuARLT) are 100% GFP-positive (Fig 
3.3B) and display the characteristic spindle-like morphology (Fig 3.3C), indicating that HuARLT 
cells are permissive for KSHV-infection. 
 
Figure 3. 3  HuARLT cells are susceptible to KSHV infection. 
A) A representative confocal image of immunofluorescence staining for viral LANA. rKSHV-HuARLT cells were cultured 
in presence of doxycycline and puromycin followed by cell fixation and LANA staining. Nuclei were visualized by DAPI 
staining, GFP is encoded by the virus. Scale bar 25 µm. B) Expression of virus-derived GFP was measured by FACS 
analysis of HUARLT cultured in presence of doxycycline and rKSHV-HuARLT cultured in presence of doxycycline and 
puromycin. C) Representative confocal images of spindle cell formation upon KSHV infection. HuARLT or rKSHV-
HuARLT were cultured in presence or absence of doxycycline, respectively, and stained with an anti-vimentin antibody and 
DAPI for better visualization. Scale bar 50 µm (Image by Ch. Lipps) 
3.1.4 KSHV establishes latency in HuARLT cells 
In order to characterize the stage of KSHV infection in rKSHV-HuARLT cells, the expression of RFP 
driven by the lytic PAN viral promoter was evaluated via fluorescence microscopy and FACS 
analysis. A significant fraction of RFP expressing cells could not be detected by any method, 
suggesting that the lytic phase is not detectable in standard cultivation conditions and the virus has 
established latency in the infected cells. It was tested, if lytic reactivation can be induced by 12-O-
Tetradecanoylphorbol 13-acetate (TPA), sodium acetate, or decitabine. However, even in presence of 
Figure 3. 2 HuARLT cells maintain properties of primary endothelial cells.  
A) Relative expression of endothelial specific genes analyzed by RT-qPCR of total mRNA isolated from primary HUVECs 
or HuARLT cells cultured in absence or presence of doxycycline for 3 days. B) Relative expression of proliferation-sensitive 
genes was measured by RT-qPCR on total mRNA of HUVEC cells cultured for 7 days either with or without 3µM FuDR. C) 
Relative expression of proliferation-sensitive genes was measured by RT-qPCR on total mRNA of HuARLT cells cultured 
in presence or absence of doxycycline. Expression levels in primary HUVECS are set to 1. D) and E) AcLDL uptake was 
measured in HUVECs or HuARLT cells by FACS analysis 7 days after treatment with FuDR or removal of doxycyline, 
respectively.  
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the agents, reactivation of rKSHV-HuaARLT cells could not be efficiently achieved (Fig 3.4A and B), 
which is in agreement with the studien in other adherent cell lines159,160. 
In order to confirm the predominant latent stage of the virus, the expression levels of typical latent 
and lytic viral genes relative to cellular ACTB was measured using RT-qPCR. The result showed 
elevated levels of latent mRNAs, such as LANA, vCyclin, vFLIP and kaposin, whereas mRNAs of 
viral lytic genes, such as PAN, kB-ZIP, ORF50, ORF45 were expressed at lower levels or could not be 
detected at all, confirming that the vast majority of infected cells had established latency (Fig. 3.4C). 
Similar to the absence of RFP expressing cells even in conditions of reactivation, expression of lytic 
viral transcripts could not be increased by addition of sodium butyrate and TPA, thus confirming lack 
of reactivation of the virus from infected cells in 2D cell culture. 
 
Figure 3. 4  KSHV establishes latency in HuARLT cells. 
A) Representative pictures of fluorescence imaging of rKSHV-HuARLT cells cultured either in presence or absence of 20 
ng/ml TPA and 1 mM sodium butyrate (SB), respectively, for 72h. Scale bar 50 µm B) FACS plots showing RFP expression 
of HuARLT and rKSHV-HuARLT cells cultured in presence or absence of 20 ng/ml TPA and 1 mM sodium butyrate (SB) 
or 100 nM decitabine (Deci), respectively, for 72h. C) Relative expression of latent and lytic viral transcripts was measured 
by RT-qPCR in latent or upon addition of 20 ng/ml TPA and 1 mM sodium butyrate, respectively, for 72h. D) Viral copy 
number and GFP expression level (MFI) of rKSHV-HuARLT cells treated for 14 days with either 25 µM GA or 100 µM 
PhA.  
3. Results 
48 
 
To confirm that the viral genome is maintained episomally in the immortalized cells the cells were 
treated with glycyrrhizinic acid (GA). GA downregulates LANA, the protein responsible for tethering 
viral episomes to the cellular genome221. rKSHV-HuARLT cells were treated with GA for two weeks. 
Then, GFP expression was determined and the viral copy number per cell was assessed by qPCR. As 
depicted in Figure 3.3D, the GA treatment induced substantial viral loss as determined by both qPCR 
for viral copy number, as well as MFI of the treated cells. This confirms that the viral genome is in an 
episomal state rather than aberrantly integrated into the cellular genome in this cell line. 
In contrast, treatment of the infected cells with phosphonoformic acid (PhA), an inhibitor of the 
lytically expressed viral DNA polymerase136, did not have an effect on the viral copy number. These 
data support the conclusion that the cells are predominantly latently infected and lytic reactivation 
does not play a role in viral maintenance in 2D culture. 
Taken together, the data shows that rKSHV.219 established a latent episomal state in HuARLT cells 
with no detectable levels of lytic reactivation. 
3.1.5 KSHV infection changes the endothelial phenotype of HuARLT cells  
Based on transcriptional profiling, it was previously shown that in virus infected cells 1839 genes 
were up-regulated by two-fold while 1693 genes were found to be down-regulated194. In order to 
evaluate to which extent these changes reflect Gene ontology pathway analysis showed that the 
differentially regulated genes are enriched in pathways connected with angiogenesis, cell migration 
and organ development (Fig. 3.5A and B).  
It has been reported that the expression profile of the cells from Kaposi’s sarcoma lesions closer 
resemble the profile of lymphatic endothelial cells (LECs) rather than blood endothelial cells 
(BECs)69. In particular, the cells from Kaposi’s sarcoma lesions express VEGFR359, the marker of 
lymphatic and precursor endothelium as well as PROX1, a master regulator of lymphatic endothelium 
cell differentiation. Infection of BEC with KSHV leads their lymphatic reprogramming and induction 
of the main lymphatic endothelial genes expression69,70. Similarly, rKSHV-HuARLT cells upregulate 
VEGFR3 and PROX1 relative to cellular ACTB as measured by RT-qPCR. In contrast, expression of 
blood endothelial specific markers, such as VEGFR1, Tie1, Tie2 and VE-Cadherin is markedly 
reduced or not detectable at all in rKSHV-HuARLT infected cells (Fig. 3.5C). Immunofluorescence 
detection of CD31, ZO-1 and CD144, other blood endothelial-specific markers, showed  
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Figure 3. 5 KSHV infection changed phenotypic characteristics of HuARLT cells. 
A) Top 20 canonical pathways enriched in Gene Ontology analysis by differentially expressed genes in the rKSHV-
HuARLT and HuARLT cells. The set of differentially expressed genes was obtained by transcriptome analysis of the cells 
via Gene arrays and visualized by ClusterProfiler203 tool. The genes were considered to be differentially regulated if 
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homogeneous expression of the markers in HuARLT cells, whereas rKSHV-HuARLT cells did not 
exhibit detectable levels of hCD31, ZO-1 or CD144 (Fig. 3.5D). Similarly, FACS analysis revealed 
that CD34 and CD146 expression was abolished in KSHV-infected cells. Interestingly, Vimentin, a 
mesenchymal marker, which is found in histological sections of oral Kaposi’s sarcoma63, was 
expressed in both KSHV-infected and non-infected HuARLTs (Fig. 3.5E). Taken together, the data 
confirm that similar to primary BEC and the cells isolated from KS lesions, HuARLT cells undergo 
lymphatic transcriptional reprogramming. 
3.1.6 Survival of KSHV-infected cells is dependent on the PI3K-mTOR pathway  
The crucial role of various cellular signaling pathways for the survival of virus-infected cells was 
previously highlighted141. To confirm the relevance of these pathways in infected HuARLT cells, the 
viability of infected cells were tested upon inhibition of the respective pathways. Differential cell 
viability was observed upon treatment of the infected and non-infected cells with rapamycin, BAY11-
7085 and LY294002, which block mTOR, PI3K and NFkB pathways, respectively. FK506, which is 
structurally related to rapamycin and shares a number of molecular targets with it, except for mTOR, 
was used as a negative control in this assay. DAPT, a small molecule inhibitor of γ-secretase and 
Notch, exhibited no difference on viability of infected and non-infected cells (Fig. 3.5D). In 
agreement with previous studies in primary cells141 these data indicate that mTOR, PI3K and NFkB, 
rather than Notch pathway are important for survival of KSHV-infected HuARLT cells. 
expression change is higher than 2 fold and adjusted p-value is less then 0.01 as determined by ANOVA test. B) Network 
visualization of selected enriched biological processes upon KSHV infection of HuARLT cells. The networks were 
assembled and visualized by EnrichMap204 tool, using Kamada-Kawai layout. The node size represents the number of genes 
assigned to a biological process and overlap is proportional to the number of overlapping genes between two nodes. The 
higher color intensity reflects lover adjusted p-value. C) Relative expression of blood or lymphatic endothelial cell markers 
was measured by RT-qPCR. The expression level of HuARLT cells was set to 1. D) Representative images of 
immunofluorescence staining of HuARLT cells and rKSHV-HuARLT cells for hCD31, ZO-1 (scale bar 100 µm, image by 
Ch. Lipps) and hCD144 (VE-Cadherin, scale bar 50 µm). Primary antibodies were detected by cy3-labeled secondary anti-
IgG antibodies. E) Expression of Vimentin, hCD34 and hCD146 was measured by FACS analysis of antibody stained 
samples. Primary antibodies were detected via APC-labeled secondary anti-IgG antibodies. F) The percentage of viable 
HuARLT and rKSHV-HuARLT cells was measured by WST assay after 3 days of treatment with 1.25 mg/ml rapamycin, 
1.25 mg/ml FK506, 10 µM BAY11-7085, 12.5 µM LY294002 or 100 µM DAPT respectively. 
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3.1.7 KSHV infection enhances tube formation of HuARLT cells in vitro 
rKSHV.219 infection of HuARLT cells leads to numerous transcriptional and phenotypic changes that 
correspond to those observed in primary endothelial cells and cells in KS lesions. To investigate 
whether the phenotypic changes described above have an impact on endothelial function of KSHV-
infected cells, we conducted Matrigel tube formation assay. The assay measures an ability of 
endothelial cells to form capillary-like structures, or tubes, and is employed to demonstrate the 
angiogenic activity of vascular endothelial cells in vitro222–224.  
To investigate the ability of KSHV-infected cells to form tubes, the cells were seeded on growth-
factor reduced Matrigel™-coated plates to achieve subconfluence and incubated overnight either in 
presence or absence of doxycycline. As control, HUVEC cells were used under the same conditions. 
Tube formation was evaluated with phase contrast microscopy. Total tubules length as well as number 
of tubules and junctions was calculated with the use of angiogenesis analyzer plugin for ImageJ 
software225. The results showed that HuARLT cells cultured in absence of doxycycline are as efficient 
 
Figure 3. 6 Infection with rKSHV promotes tubules formation in Matrigel assay. 
1.2*105 HUVEC, HuARLT or rKSHV-HuARLT cells were seeded onto Matrigel coated 24-well plates either in presence or 
absence of doxycycline. Tube formation was evaluated 16 hours later by bright field microscopy. A) Representative images, 
scale 500 µm. B, C, D) Quantification of the number of junctions, number of tubules and length of tubes from independent 
fields of view of a representative experiment, each dot represents an independent field of view.  Statistical significance is 
shown by asterisks: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, **** p ≤ 0.0001.  
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in forming tubules as primary HUVECs. Interestingly, culture in presence of doxycycline 
significantly reduced the angiogenic potential of HuARLT cells in this assay.  
Of note, KSHV infection induced a significant increase in tube length, number of tubes and junctions 
as compared to both uninfected HuARLT and primary HUVECs. This is in line with the studies 
showing that KSHV infection increases the ability of primary HUVEC cells to form tubes in matrigel 
assay even in serum-deprived conditions 141. Thus, these results confirm that HuARLT cell undergo 
similar change in endothelial cell function as primary HUVEC cells do.  
3.1.8. KSHV infection increases the invasiveness of the cells in 3D cell culture 
To investigate the invasive properties of KSHV infected cells, rKSHV-HuARLT cells as well as non-
infected HuARLT cells were embedded into fibrin gels, as was previously described86 and the ability 
to form sprouts was observed by phase contrast microscopy for 7 days (Fig. 3.7A).  
Both rKSHV-HuARLT and HuARLT cells form visible sprouts 3 days after embedding, however, the 
sprouting has different nature in these cells. Upon day 5-7 of cultivation, the sprouts formed by 
HuARLT cells transform into vessel-like structures growing out from the spheroid body. Of note, 
only proliferating HuARLT are capable of building these structures, whereas non-proliferating cells 
fail to do so. In contrast, spheroids formed from rKSHV-HuARLT cells continue invasive growth and 
sprouting without developing vessel-like structures in both presence and absence of doxycycline.  
Together, the results indicate that transcriptional reprogramming of KSHV-infected HuARLT cells 
described in chapter 3.1.5 is accompanied with loss of vessel formation capacity and gain of an 
invasive phenotype. 
3. Results 
53 
 
3.1.9 rKSHV-HuARLT induce lesions upon transplantation into mice  
To investigate the tumorigenic potential of rKSHV-HuARLT cells, rKSHV-HuARLT as well as the 
control HuARLT cells were aggregated to spheroids and transplanted into immunocompromised 
Rag2-/-γc-/- mice according to a previously described protocol194 (Fig. 3.8A). After 4 weeks, the plugs 
were isolated. Sections were stained for human vimentin and the morphology of transplanted cells 
was examined via microscopy (Fig.3.8B). As described before, HuARLT cells form functional blood 
vessels upon transplantation in presence of doxycycline, whereas rKSHV-HuARLT cells form KS-
like lesions194. The lesions were positive for virus encoded GFP and LANA well as for human ALU 
sequences and hCD141, but not for mouse CD31, confirming that they are originated from 
transplanted KSHV-infected cells. (Fig. 3.8C).  
 
Figure 3. 7 KSHV induces the migration and invasiveness of the infected cells. 
A) Schematic depiction of experimental procedure. B) Phase contrast microscopy of HuARLT and rKSHV-HuARLT 
spheroids embedded into fibrin gels was performed on day 0, day 3 and day 7. Scale bar 200 µm. 
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Figure 3. 8  Characterisation of rKSHV-HuARLT cells upon transplantation to Rag2-/-γc-/-. 
A) Experimental setup. B) Representative pictures of engrafted cells isolated 4 weeks after transplantation upon staining for 
human vimentin. Magnification 100x. C) Lesions obtained from transplanted rKSHV-HuARLT cells were stained for H&A 
as well as ALU-positive nuclei, GFP, LANA, CD141 (staining was performed by G. Büsche, magnification 250x) and 
mouse CD31 (magnification 50x). Representative immunohistochemistry sections are shown.  
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3.2. Molecular mechanism of maintenance of KSHV in latently infected 
endothelial cells 
Unlike KSHV-infected B-cells, spindle cells isolated from KS lesions153–155 as well as newly KSHV-
infected HUVECs156 fail to maintain viral episomes during cell culture using standard 2D conditions. 
It led to the hypothesis that viral loss in endothelial cell culture is a consequence of in vitro cell 
proliferation. If latent viral episomes are not replicated as efficiently as the host cell genome, rapidly 
proliferating endothelial cells will lose the viral genome. This indicates that not spindle cells, but 
rather slowly proliferating memory B-cells are the primary reservoir of KSHV in the patients156. 
However, this observation is in conflict with the clinical data showing that depending on the stage of 
the disease, up to 90% of spindle cells are infected with the virus59. This chapter will describe 
differential KSHV maintenance in latently infected HuARLT cells upon various culture conditions 
and the elucidation of underlying molecular mechanisms involved in viral maintenance.  
3.2.1. Maintenance of KSHV upon cultivation without selection pressure 
rKSHV.219 encodes the puromycin resistance gene, which allows selection of infected cells in 
culture, thereby achieving 100% KSHV-positive population, as accessed by FACS analysis of virus-
encoded GFP. Upon culture rKSHV-HuARLT cells in presence of doxycycline and without 
puromycin for 2 weeks, a fraction of GFP-negative, LANA-negative cells appear in the culture, as 
was observed by LANA immunofluorescence staining and FACS analysis (Fig. 3.9A and B). 
Similarly, the number of viral genomes measured by qPCR is reduced from 9.19±1,88 to 4,61±0,61 
viral copies per cell upon cultivation without selection pressure for 14 days (Fig. 3.9B). The viral 
copy number as well as the amount of GFP-positive cells decreased further upon prolonged 
cultivation without puromycin (Fig. 3.9B and C).  
Taken together, the findings indicate that similar to primary cells and KS-isolated spindle cells, 
proliferating rKSHV-HuARLT fail to retain the virus upon prolonged cultivation without selection 
pressure. 
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Figure 3. 9 Viral loss in proliferating rKSHV- HuARLT cells. 
FACS analysis (A) and fluorescence imaging (B) of the rKSHV-HuARLT cells cultured in presence of doxycycline and in 
absence of puromycin for 14 days indicate appearance of GFP-negative cells upon cultivation without selection pressure. 
Scale bar 50 µm. C) Relative viral copy number of proliferating rKSHV-HuARLT cells was measured by qPCR on day 0, 14 
and 38 upon cultivation without puromycin. D) Percentage of GFP positive cells was measured by FACS analysis of 
proliferating rKSHV-HuARLT cells cultured with and without puromycin for 33 days. 
3.2.2. Viral loss in cell culture is not only the result of cell proliferation 
Based on the observation that newly infected SLK and primary HUVECs fail to retain viral copies in 
vitro, it has been hypothesized that the loss of KSHV in endothelial cells is connected with cellular 
proliferation156. In particular, if viral episomes replicate less efficient than the cellular genome, every 
cell division will result in reduction of viral copies per cell. To test this hypothesis we investigated 
viral loss in rKSHV-HuARLT cells either in absence or in presence of doxycycline. First, the 
proliferation capacity of KSHV-infected cells was tested. To this end, the cells were cultured for 13 
days either in presence or absence of doxycycline. Similarly to non-infected HuARLT, rKSHV-
HuARLT cells exhibit robust cell growth in presence of doxycycline, whereas cell numbers in a 
culture without doxycycline remains constant (Fig. 3.10A), showing that infection with rKSHV does 
not interfere with doxycycline-dependent growth control.  
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After it was established that proliferation status of rKSHV-HuARLT cells depends on presence of 
doxycycline, the effect of proliferation on the viral copy number was investigated. The cells were 
cultured without selection pressure with or without doxycycline for 14 days followed by evaluation of 
viral copy number either by qPCR of viral DNA or by counting LANA dots per cells, as the latter has 
been shown to reflect viral copy numbers181. As a result, the population cultured in presence of 
selection pressure had 10.53±0.56 virus per cell as determined by qPCR and 10.55±4.47 as measured 
by immunofluorescence, indicating that both readouts give rise to consistent results. Strikingly, both 
proliferating and non-proliferating cells show a viral copy number reduction to 5.77±1.86 in presence 
of doxycycline and 5,43±1,07 in absence of doxycycline as measured by qPCR (Fig. 3.10B). The data 
shows that the proliferation status of the cells does not have an impact on KSHV maintenance, 
rejecting the hypothesis that viral maintenance in cell culture is simply a result of an imbalance 
between cellular and viral replication. 
3.2.3 3D culture conditions rescue for viral maintenance 
To investigate, whether viral maintenance depends on cell culture conditions, viral load per cell was 
measured in the cells cultured in standard 2D or  advanced 3D cell culture for 14 days. For this assay 
the spheroids were embedded in Matrigel, rather than fibrin, as described before86,194, because fibrin 
cultures are not stable enough to support long-term cultivation and were completely degraded on day 
9-10 of cultivation. Matrigel-embedded spheroids were cultured in presence of doxycycline and in 
absence of puromycin selection pressure. As a result, the cells cultured in 2D cell culture had 
9,61±0,92 copies per cell in presence of puromycin and 4,82±0,49 copies per cells in absence of 
puromycin, whereas cell cultured in 3D had 9.75±2.66 viral copy per cell with no significant 
difference from puromycin-treated cells (Fig. 3.11A).  
 
Figure 3. 10  KSHV loss in cell culture is not the result of cellular proliferation. 
A) KSHV does not interfere with doxycycline-dependent growth control. 104 cells were seeded on gelatin-coated plates 
and cultured for 13 days with or without doxycycline, respectively. Cell numbers were counted every 2-3 days, 4 
replicates were evaluated per each time point. B) rKSHV-HuARLT cells were cultured without selection pressure in 
presence or absence of doxycycline for 14 days followed by either immunofluorescence LANA staining or DNA isolation 
and measuring of viral load by qPCR. 3 replicates were analyzed per condition and independent fields of view per 
replicate were alalyzed to measure LANA dot count. 
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In order to confirm that 3D cell conditions are supportive for viral maintenance in vivo, viral copy 
number change was investigated in humanized mouse model. To this end, rKSHV-HuARLT cells 
were transplanted as described before194 and the plugs were isolated 1 month after transplantation. In 
order to discriminate human and mouse cells, the cells isolated from mice, the plugs were stained for 
human vimentin and isolated by FACS. Based on this cell fraction, the viral copy number per cell was 
measured. The analysis showed 12,23±3,97 copies for the engrafted human cells with no significant 
difference to the cells cultured in vitro in presence of puromycin. Similarly, also the amount of GFP-
positive cells in the resulting population was significantly higher than in 2D culture, confirming the 
results observed by qPCR (Fig. 3.11B). 
These observations are in agreement with previous studies indicating a higher LANA dots-per-cell 
count in 3D cultured endothelial cells86 as well as improved KSHV maintenance in 3D cultured B 
cells172. Taken together, the data indicate that advanced 3D culture or in vivo conditions are required 
for viral maintenance. 
3.2.4 Lytic reactivation in 3D cell culture conditions 
To investigate whether mechanisms of viral maintenance differ between 2D and 3D cell culture, the 
cells were treated with of GA and PhA, targeting LANA and viral DNA polymerase respectively, in 
3D cell culture conditions. To this end, the cells were cultured for 14 days in different cell culture 
conditions either in presence or in absence of inhibitors. Similarly to latently infected cells in 2D, 3D 
cultured cells were susceptible to GA, confirming that KSHV established episomal maintenance in 
3D. However, viral copy number in 3D was reduced by PhA from 10.97±1.12 to 6.84±0.17 viral 
copies per cells, in contrast to standard 2D cell culture conditions (Fig. 3.4D). The data indicate 
 
Figure 3. 11  Viral maintenance is supported by 3D cell culture conditions and is also observed upon transplantation in vivo. 
 A) rKSHV-HuARLT cells were cultured either in standard 2D culture or 3D matrigel culture for 14 days in presence of 
doxycycline followed by FACS analysis and viral copy number measurement by qPCR. Control refers to the cells cultured in 
2D conditions in presense of selection pressure. B) Viral copy number and presence of GFP positive cells were quantified in 
rKSHV-HuARLT cells isolated from mice 1 month after transplantation or cultured in standard 2D culture in presence of 
doxycycline. For in vivo tests doxycycline was added to the drinking water throughout the experiment.  
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indicating that the mechanism of viral maintenance in 3D depends on viral DNA polymerase (Fig. 
3.12A) and differs from the one observed in 2D culture conditions. 
rKSHV.219 encodes RFP, driven by viral immediate early PAN promoter, which allows monitoring 
of lytically reactivated cells in culture. To address the role of lytic reactivation, the amount of RFP 
cell was measured by FACS analysis after 3 and 14 days of 3D cultivation. Of note, no significant 
increase in RFP expression in any of these conditions (Fig. 3.12B). Thus, expression of viral lytic 
transcripts was measured in cell cultured in 3D for 3 days. No elevation in expression of tested lytic 
genes could be observed in either of the conditions. Rather, ORF50, k-bZIP, ORF45, ORF33 
transcripts were even downregulated in 3D cell culture (Fig. 3.12C).  
To investigate, whether downregulation of viral genes is restricted to lytic transcripts only, expression 
of viral latent (LANA, vFLIP, vCyclin) was measured by RT-qPCR. Unexpectedly, also the latent 
genes were expressed to a lower level  (Fig. 3.12D). Similarly, expression of GFP, which is controlled 
 
Figure 3. 12  KSHV reactivation in 3D cell culture conditions. 
A) Viral copy number of rKSHV-HuARLT cells embedded in Matrigel 3D cell culture for 14 days and treated with 25 µM 
GA or 100 µM PhA; untreated rKSHV-HuARLT cells were used as a control. B) FACS analysis on RFP expression of 
rKSHV-HuARLT cells either cultured in 2D or in 3D cell culture conditions for the indicated days. C) Lytic, latent (D) and 
GFP (E) gene expression in rKSHV-HuARLT cells cultured in indicated cell culture conditions for 3 days was measured by 
RT-qPCR relative to the cellular housekeeping gene NICE3 (c1orf43); n.i.: non-infected HuARLT cells. G) Percentage of 
GFP-positive cells and MFI (F) in rKSHV-HuARLT cells cultured in different cell culture conditions for 3 days as analyzed 
by FACS.  
3. Results 
60 
 
by cellular EF1a promoter, but encoded by the viral episome, was reduced, as observed by RT-qPCR 
(Fig. 3.12E). Although the amount of GFP-negative cells did not decrease upon 3 days of 3D culture 
(Fig 3.12F), a significant decrease of MFI could be observed by FACS-analysis (Fig. 3.12G), 
confirming lower levels of GFP expression in 3D cell culture. 
3.2.5 Role of hypoxia in KSHV maintenance 
According to their structure, 3D spheroid cultures develop gradients of various factors (e.g. nutrients, 
catabolites) and, particularly, oxygen (reviewed in165). The spheroids cultured in standard cell culture 
conditions without additional oxygen supply form a hypoxic core, expressing various hypoxic 
markers226,227. KSHV genome carries hypoxia-responsive regions228 and hypoxic conditions induce 
viral reactivation36,229,230. To test whether hypoxic conditions alone could be responsible for better 
maintenance of the virus in 3D culture and are sufficient to increase viral copy number in 2D the cells 
were subjected to hypoxic conditions. To this end, the cells were cultured either in normoxic (20% 
O2) or hypoxic conditions (5% O2). Treatment of the cells in the normoxic chamber with CoCl2, a 
chemical inducer of HIF-1a, was utilized as another way to mimic hypoxic conditions in cell culture. 
The cells were treated for 14 days followed by measurement of the viral copy number. As a result, 
neither the cells cultured in the hypoxic chamber, nor the chemically induced hypoxic conditions were 
able to increase viral copy number compared to the standard normoxic 2D culture (Fig. 3.13A).  
It has been shown that increase in media volume can significantly impact the pericellular oxygen 
concentration231. To enhance the effect of hypoxic chamber the cells were cultured in 6 well plates 
either with 2,5 ml of media (medium height 2 778 µm, corresponding to ≈2.83% of oxygen) or 5 ml 
 
Figure 3. 13  KSHV maintenance is not affected by hypoxic cell culture conditions. 
A) The viral copy number of rKSHV-HuARLT cells cultured for 14 days either in normoxic (20% O2), hypoxic (5% O2) 
conditions or in presence of 100 µM of CoCl2 was measured by qPCR. rKSHV-HuARLT cells cultured in normoxic 
conditions in presence of selection pressure were used as a control. B) Percent of GFP positive cells in rKSHV-HuARLT 
cells cultured either in normoxic conditions (20% O2) or in hypoxic conditions enhanced by increased media volume without 
selection pressure as quantified by FACS analysis on day 4 and day 10. As control rKSHV-HuARLT cells cultured in 
presence of puromycin in normoxic conditions were used.   
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of media (medium height 5 556 µm) for 10 days. The amount of GFP-positive cells was measured by 
FACS analysis on day 4 and day 10. In both time points the amount of GFP-positive cells did not 
differ between the conditions (Fig.3.13B). Taken together, the data indicates that hypoxic conditions 
alone are not sufficient to increase viral copy number in 2D culture and cannot explain better viral 
maintenance in 3D. 
3.2.6 The PI3K-mTOR pathway is deregulated in 3D cell culture conditions 
In order to determine which pathways contribute to viral maintenance in 3D cell culture, the 
expression profile of cells was analyzed by RNA-Seq. To this end, in rKSHV-HuARLT cells were 
cultured in either standard cell culture conditions or in 3D spheroids.  Total RNA was extracted from 
these cells after 3 days of cultivation and subjected to next generation sequencing. The raw data 
obtained during sequencing were mapped to the reference human and KSHV genomes. As a result, 
736 cellular genes were upregulated and 542 cellular genes were downregulated upon 3D cultivation 
(Fig 3.14A). Differentially regulated genes strongly enriched in several cellular pathways, among 
which are: pathways in cancer, PI3K-Akt and MAPK pathways (Fig. 3.14B). Of note, downstream 
targets of Pi3K-Akt pathway were not homogeneously regulated (Fig. 3.14C and S3). 
In order to confirm these data, relative expression of selected candidate genes was evaluated by RT-
qPCR in an independent experiment. RT-qPCR analysis confirmed that TLR2, Jak2, PI3K, Notch1, 
Hes1 and S6K1 were significantly upregulated in 3D culture conditions with a fold change of 1,4 or 
higher. Interestingly, TLR2 gene showed a 2.6fold upregulation in 3D cell culture by RT-qPCR in 
contrast to downregulation by RNA-Seq. In contrast, expression of TLR4, cRaf, Jag1, Hey1, MEK and 
Akt genes was not significantly changed, as measured by both RT-qPCR and RNA-Seq. Although 
mTOR gene expression appeared to be moderately upregulated in the RNA-Seq experiment, the data 
could not be confirmed by RT-qPCR (Fig. 3.14D). Taken together, the RT-qPCR data largely 
confirmed the RNA-Seq analysis and indicated upregulation of several genes associated with the 
PI3K-Akt pathway. However, it has to be taken into account that the pathway is mainly regulated on 
post-transcriptional level; thus, evaluation of the contributing genes on the level of RNA can only be 
taken as a hint. This might also explain the heterogeneous deregulation of individual factors as well as 
the minimal fold change.  
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Figure 3. 14  Upregulation of PI3K pathway in 3D cell culture. 
A) Volcano plot of total deregulated genes upon 3 days of cultivation in 3D cell culture conditions as determined by RNA-
Seq. Green indicates the genes downregulated in 3D culture and red indicates the genes upregulated in 3D cell culture. Fold 
change of 2 and adjusted p-value of 0.05 were selected as a threshold (data analysis by R. Geffers). B) Top 9 canonical 
pathways enriched in KEGG pathways by differentially expressed genes from the RNA-Seq analysis of rKSHV-HuARLT 
cell cultured either in 2D or 3D cell culture for 3 days (data analysis by R. Geffers). C) PI3K pathway regulation as 
determined by RNA-Seq analysis. The genes, upregulated more then 1.5 fold are indicated in dark grey, downregulated gene 
is shown in white and the genes with no detected change of expression are shown in light grey. C) Relative expression of the 
selected genes from PI3K pathway as measured by RT-qPCR. The expression level in 2D culture was set to 1. 
3.2.7 Inhibition of the PI3K-mTOR pathway induces viral loss in 3D cell culture 
Previous studies indicate that the PI3K, as well as the Ras-cRaf-MAPK and the NF-kB pathways are 
stimulating KSHV reactivation38,39. Another study shows that 3D cell culture of KSHV-infected cells 
leads to higher viral gene expression and upregulation of Notch signaling86. Taking into account the 
multiple interactions between these pathways, it is not possible to distinguish them based on the 
KEGG database. Rather, they are recognized as a single PI3K-Akt pathway. In order to determine 
which part of the pathway is responsible for better viral maintenance in 3D cell culture, the cells were 
embedded into matrigel matrix and cultured for 14 days in presence of small molecules that 
specifically target the activity of various proteins within these pathways (Fig. 3.15A). 
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As a result, treatment with LY294002, a chemical inhibitor of PI3K, as well as treatment with 
Rapamycin, an inhibitor of mTOR, led to the reduction in viral copy number in 3D culture up to 20%, 
whereas FK506, which shares a number of molecular targets with rapamycin, except for mTOR 
showed no effect. Interestingly, the inhibitors showed no significant effect in 2D conditions. (Fig. 
3.15B). In contrast, inhibition of the factors in the associated Notch, NF-kB, or Ras-cRaf pathways 
showed no influence of viral copies number both in 2D and 3D culture. Interestingly, GW5074, an 
inhibitor of cRaf even increased the viral copy number both in 2D and 3D up to 30%. 
Taken together, the data indicate that the PI3K-Akt-mTOR axis is crucial for viral maintenance in 3D 
cell culture, but not the other branches of the pathway. 
  
Figure 3. 15  Inhibition of the PI3K-Akt-mTOR pathway leads to viral loss in 3D culture. 
A) Schematic representation of the pathway and the inhibitors used. B) Relative viral copy number was measured in rKSHV-
HuARLT cells after 14 days of treatment with the selected compounds: 2.5 µM LY294002, 2.5 µg/ml rapamycin, 2.5 µg/ml 
FK506, 10 µM U0126, 10 µM GW5074, 2,5 µM Bay7085, 50 µM DAPT, 5 µM manumycin. Viral load in the respective 
control samples was set to 1. 
3.2.8 Differential role of the DNA damage response in viral maintenance in 2D and 3D cell 
culture 
KSHV infection induces DNA damage response early upon infection. The activation of the pathway 
and specifically ATM-induced H2AX phosphorylation is beneficial for establishment of latency and 
viral maintenance108. Another study indicates that both DNA-PK dependent protein kinase (DNA-PK) 
and the MRE11/Rad50/MBS1 (MRN) complex play a differential role in KSHV reactivation. The 
data suggest that the MRN complex supports KSHV reactivation, whereas DNA-PK/Ku70/Ku80 
complex restricts it232. In order to determine if DNA damage response and in particular the MRN 
complex plays a role in KSHV maintenance, the pathway was perturbed by small molecules (Fig.16 A 
and B). 
To this end, rKSHV-HuARLT cells were either cultured in standard 2D cell culture conditions, or in 
the previously described matrigel-embedded 3D culture conditions in presence of the inhibitors. The 
cells were treated for 14 days followed by evaluation of the relative viral copy number. In accordance 
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with the literature data, inhibition of ATM led to substantial viral loss in both 2D and 3D cell culture, 
supporting the conclusion that it is required for maintenance of KSHV latency. Interestingly, 
treatment with NU7441, a chemical inhibitor of DNA-PK, resulted in viral loss, which was more 
pronounced in 2D rather than 3D culture conditions. On the contrary, treatment, with mirin, an 
inhibitor of the MRN complex led to a moderate increase in viral copy number up to 15% in 2D cell 
culture. However, it had no effect in 3D culture.  
Taken together, the data suggest that differential regulation of the DNA damage response pathway in 
2D and 3D cell culture might contribute to the differential viral maintenance. 
  
Figure 3. 16  Role of the DNA damage response pathway in KSHV maintenance. 
A) Schematic representation of the pathway and the inhibitors used. B) Relative viral copy number was measured in rKSHV-
HuARLT cells after 14 days of treatment with the selected compounds: 10 µM Ku55933, 1 µM Nu7441 or 10 µM mirin. 
Viral load in the respective control samples was set to 1. 
3.2.9 Role of Eya phosphatases in KSHV maintenance 
Recent studied demonstrated that H2AX phosphorylation on the Tyr142 site regulated by eye absent 
(Eya) phosphatases plays a crucial role in apoptosis or DNA repair decisions93. Mammalian cells 
express four Eya phosphatases, known as Eya 1-4. Of note, careful evaluation of the RNA array data 
revealed that expression of one of the phophatases, Eya1, was 2-fold lower in 3D cell culture, as 
determined by RNA-Seq. 
To confirm this finding, total mRNA was isolated from independent experiment and the expression of 
all four Eya genes, as well as their target H2AX was evaluated via RT-qPCR. The result showed 
significant downregulation of Eya1, Eya2 and Eya4 in 3D cell culture, confirming the RNA-Seq 
analysis. The expression of H2AX did not change upon different cell culture conditions which in line 
with the posttranslational rather than a transcriptional regulation of this protein.   
These results open the possibility that Eya expression in 2D conditions might compromise viral 
maintenance.  To investigate whether downregulation of Eya expression in 3D culture conditions 
could be the reason for better viral maintenance, it was tested if blocking of Eya would result in better 
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maintenance of the virus. To this end, rKSHV-HuARLT cells were cultured in 2D conditions and 
treated with MLS000544460, a small molecule inhibitor of Eya2233,234 for 14 days followed by viral 
copy number analysis. 3D cell culture was used as control. However, the treatment of the cells with 
the inhibitor did not result in an increase of viral copy number in 2D as well as in 3D cell culture 
condition. Rather, a moderate decrease in viral copy number compared to the control was observed. 
These results thus suggest that Eya2 is not a negative factor but rather supports viral maintenance.  
  
Figure 3. 17  Role of Eya phosphatases in KSHV maintenance. 
A) The relative expression of Eya phosphatases in 2D or 3D rKSHV-HuARLT cell culture was measured by RT-qPCR after 
3 days of cultivation. Expression levels in 3D culture were set to 1. B) The relative expression of H2AX in rKSHV-
HuARLT cells cultured in 2D or 3D conditions was measured by RT-qPCR on days 3 and day 14 of cultivation. Expression 
levels on day 1 of culture were set to 1. C) Relative viral copy number in rKSHV-HuARLT cells cultured for 14 days in 2D 
or 3D cell conditions in presence of 5 μm MLS000544460. The viral copy numbers in absence of the drug in the respective 
culture conditions are set to 1. * indicated p-value less than 0,05 
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3.3 rKSHV-HuARLT for screening and validation of novel antiviral compounds 
HuARLT cells closely mimic the changes observed in primary cells upon KSHV infection. They 
undergo transcriptional reprogramming, which corresponds to lymphatic transdifferentiation, as we as 
endothelial-to-mesenchymal transition. Moreover, rKSHV-HuARLT cells depend on PI3K and NF-
kB pathways for survival, as described for primary HUVEC cells. Together with transcriptional 
changes, the cells also undergo phenotypic and functional transformation, as shown by loss of the 
ability to form vessels and acquisition of the invasiveness in 3D culture as well as in vivo. Taken 
together, these properties make rKSHV-HuARLT cells an attractive model for KSHV-induced 
tumorigenesis. In this chapter the relevance and the predictive power of the system will be evaluated 
upon treatment with compounds with known pharmacological targets, followed by evaluation of novel 
compounds for their ability to reduce viral load and decrease invasiveness in 3D cell culture. 
3.3.1 Purging cells from virus abolishes the tumorigenic phenotype  
From existing literature data it remained unclear if the loss of the viral genome could revert the 
phenotype of infected cells and abrogate tumor formation in vivo. To this end, rKSHV-HuARLT cells 
were cultured for 38 days without selection pressure and isolated the GFP negative cells by FACS 
(designated as KF-HuARLT cells, Fig. 3.18A). Analysis of the viral copy number in KF-HuARLT 
cells confirmed a significant reduction of viral genomes down to 0.07±0.04 copies per cell indicating 
the absence of the KSHV genome in the vast majority of these cells (Fig.3.18 B).  
To see if loss of KSHV reverted the transcriptional profile of the cells, total RNA was isolated and 
used for gene array analysis. Pathway analysis showed that differentially expressed genes upon loss of 
KSHV enriched pathways in angiogenesis, cell migration and organ/tissue development (Fig. 3.18C 
and D). These changes are opposite to those observed between rKSHV-HuARLT and HuARLT cells, 
suggesting that the cells reverted their phenotype upon loss of the virus. 
To investigate if the transcriptome changes of KF-HuARLT cells would result in a reduced tumor 
potential, KF-HuARLT as well as the control rKSHV-HuARLT and HuARLT cells were aggregated 
to spheroids and transplanted into immunocompromised Rag2-/-γc-/- mice. After 4 weeks, the plugs 
were isolated. Sections were stained for human vimentin and the morphology of transplanted cells 
was examined via microscopy. The virus-infected rKSHV-HuARLT cells formed KS-like lesions as 
described above (see section 3.1.9). Also transplantation of KF-HuARLT cells resulted in engraftment 
of individual cells. However, no KS-like lesion could be found indicting lack of tumorigenic potential 
of these cells (Fig.3.18E). Thus, elimination of viral genomes from KSHV-infected HuARLT cells 
completely reverted the tumorigenic phenotype and impaired the formation of lesions indicating that 
continuous expression of KSHV genes is crucial for tumor formation. 
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Figure 3. 18  Purging rKSHV-HuARLT cells from the virus. 
A) Flow cytometry of non-infected HuARLT cells as well as rKSHV-HuARLT cells upon culture in presence or absence of 
puromycin for 38 days. The gate used to sort the GFP-negative KF-HuARLT cells from the puromycin-free culture 
conditions is indicated. B) Viral load of the indicated cell populations as assessed by qPCR. C) Top 20 canonical pathways 
enriched in Gene Ontology analysis based on the differentially expressed genes in the infected rKSHV-HuARLT and purged 
KF-HuARLT cells. The set of differentially expressed genes was obtained by transcriptome analysis of the cells via gene 
arrays and is visualized with the help of the ClusterProfiler203 tool. The genes were considered to be differentially regulated 
if the change of expression was higher than 2fold and if the adjusted p-value was less then 0.01 as determined by ANOVA 
test. The size of the nodes reflects the number of contributing genes (‘count’) and the colour code indicates the significance 
level. D) Network visualization of selected enriched biological processes upon purging rKSHV-HUARLT cells from the 
virus. The networks were assembled and visualized by the EnrichMap204 tool, using the Kamada-Kawai layout. The node 
size represents the number of genes assigned to a biological process and overlap is proportional to the number of overlapping 
genes between two nodes. The higher color intensity reflects a lower adjusted p-value. E) Representative pictures of 
engrafted cells isolated 4 weeks after transplantation upon staining for human vimentin. Scale bar 100µm. 
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3.3.2 Establishment of in vitro assays for compound validation 
Loss of tumorigenic properties upon elimination of the virus indicates that the reduction of viral copy 
number is a useful parameter to identify antitumor compounds. Several therapeutic strategies targeting 
lytic reactivation of the virus were proposed recently, however, targeting the predominant latent stage 
of the virus is still a challenge124. Chapter 3.2 showed that KSHV maintenance crucially depends on 
the cell culture conditions. Although it is a common understanding that viral maintenance is largely 
governed by latent proteins chapter 3.2 indicates that viral maintenance relies on a tightly regulated 
balance between latency and lytic reactivation. 
To consider this complexity, different assay systems were established (summarized in Figure 3.19A). 
3D cell culture conditions were employed since they represent a physiologically relevant system, 
where most of the cells are latently infected with only minor proportion of cells undergoing lytic 
reactivation, resembling situation within the tumors. Treatment of 3D spheroid cultures with GA 
(which impairs LANA association) and with PhA (inhibitor of viral DNA polymerase) resulted in a 
significant reduction of the viral load (Fig. 3.12A), indicating that the system is sensitive to inhibitors 
of both latent and lytic replication.  
A 2D cell culture system was also tested for validation of antiviral compounds, since it allows 
selection of the compounds selectively targeting latent virus. As depicted in Figure 3.4D, treatment of 
cells with GA induced substantial viral loss as determined by qPCR and FACS analysis. In contrast, 
treatment of the infected cells with PhA did not have an effect on the viral copy number and GFP 
expression. These data indicate that the 2D cell culture system is highly selective for inhibitors of 
viral latent proteins.   
Although purging cells completely from the virus reverted their tumorigenic phenotype, it is unclear 
how compounds which only partially reduce viral load would impact invasiveness of the infected 
cells. For evaluation of the invasiveness of KSHV-infected cells upon compound treatment a 3D 
culture system was adapted that was previously described for KSHV-infected primary endothelial 
cells86. rKSHV-HuARLT cells were first aggregated to spheroids and then embedded in a fibrin 
matrix. Three days after embedding, the KSHV-infected cells exhibited pronounced sprouting and 
invaded into the surrounding matrix (Fig. 3.19B). To validate the specificity of the assay with respect 
to KSHV, the effect of KSHV-specific inhibitors on sprouting in 3D culture conditions was 
investigated. To this end the cell were treated with GA, PhA, and rapamycin, which is shown to 
reduce tumor progression in post-transplant KS patients as well as inhibit KSHV-induced 
angiogenesis139. The embedded spheroids were treated with the compounds for five days. The effect 
of the compounds was evaluated by microscopy and quantified by measuring the area covered by 
sprouts and relating it to the spheroid body area in the same section (Fig. 2.1). Quantification revealed 
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a significant reduction of sprouting for GA and rapamycin. In contrast, treatment with the control 
drugs FK506 and PhA did not reduce the sprouting activity (Fig. 3.19C).  
Together, the three assay systems allow selection of the compounds, which reduce viral copy number 
both in strictly latent conditions and with a limited level of viral reactivation, as well as directly 
access virus-induced invasiveness. Moreover, these test systems are sensitive to inhibitors with known 
mechanisms of action, which highlights that the systems are appropriate to test antiviral and antitumor 
activities of novel compounds. (3.19A). 
  
Figure 3. 19  In vitro systems for validation of novel anti-KS compounds. 
A) Schematic representation of the tests used for validation of the hits in vitro. B) Phase contrast microscopy of 
representative 3D spheroids before and 3 days after embedding in fibrin gels. Scale bar 50 µm. C) Relative sprouting index 
upon treatment of rKSHV-HuARLT cells with GA, PhA, Rapamycin or FK506 for 5 days. Statistical significance is 
indicated by asterisks: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.  
3.3.3 Evaluation of novel compounds for viral loss and invasiveness in 2D and 3D culture 
models 
To search for novel anti-KSHV agents in a pilot screen,  a library of 260 natural compounds was 
studied in a previously described reactivation assay in KSHV-infected BJAB cells (Brk.219 
cells)211,212. The library mainly consisted of secondary metabolites from Myxobacteria, which were 
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selected by previous natural product screening programs235. The supernatant from compound-treated 
reactivated Brk.219 cells was used to infect HEK 239T cells. Infection rate of HEK 293 was 
measured via fluorescence microscopy. Fig. 3.20A indicates the compounds that showed reduction of 
GFP expression in HEK293 cells and at the same time exhibited low to moderate toxicity in Brk.219 
cells. 
To evaluate the capability to reduce viral load in latently KSHV-infected endothelial HuARLT cells 
26 compounds were selected including pretubulysin D, a chemically accessible precursor of 
tubulysins197. First, their impact on viral copy number was tested in KSHV-infected HuARLT cells 
using drug concentrations that had little influence on cell viability (Table 2.8). The KSHV latently 
infected HuARLT cells were cultured in standard 2D conditions and treated with the compounds for 
two weeks followed by evaluation of viral copy number by qPCR. Out of the 26 compounds tested, 
seven showed a reduction of the cellular viral load to 75%: epothilon E, myxochelin A, eliamid, 
saframycin Mx1, stigmatellin F, chondramides B and C (Fig. 3.20B). This set of compounds was 
tested under the more physiologically relevant 3D conditions. To this end, matrigel embedded 
spheroids formed from KSHV-infected cells were treated for 14 days with the compounds and then 
evaluated for the viral copy number per cell. A total of nine compounds were identified that showed a 
reduction to 60%. In addition to five compounds that already showed positive effects in the 2D assay 
(epothilon E, myxochelin A, eliamid, chondramides B and C) four compounds showed copy number 
reductions in 3D culture only: trichangion, pellasoren, tubulysin A, tubulysin X (Fig. 3.20C). 
To investigate whether the selected compounds have an impact on the cell invasiveness in 3D culture 
conditions, their effect on the cell’s sprouting activity was evaluated in 3D cell culture. To this end 
fibrin gel embedded spheroids produced from rKSHV-HuARLT cells were treated with the 
compounds for 5 days followed by evaluation of the sprouting index. Overall, 13 compounds 
significantly reduced sprouting to 60% or less in the 3D sprouting assay, indicating pronounced 
reduction in the invasive potential of the cells (Fig. 3.20D). In Fig. 3.20E, the results of the three in 
vitro assays are summarized. 
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3.3.4 Validation of hits in vivo 
Four compounds with various degrees of inhibition in the three in vitro test systems were selected 
investigated for the ability to reduce the formation of KS-like lesions in the xenograft model. 
Chondramid B was chosen as a compound that significantly reduced the viral load in 2D and 3D 
culture, but with a moderate effect on the sprouting index. In contrast, pretubulysin D and epothilon B 
were selected for their strong effect on sprouting but no significant effect on the viral copy number. 
As a drug with minor activities we selected soraphen A. In addition, we used the mTOR inhibitor 
rapamycin (and its control FK506) as well as PhA with known antiviral activities. Starting directly 
after transplantation of the virus-infected cells, the mice were treated with the respective drugs for 4 
weeks. Then, the mice were sacrificed and the plugs were isolated. The lesion size was assessed by 
microscopy analysis of vimentin stained sections.  
While the control compound FK506 showed no significant effect on tumor size, a certain reduction of 
lesion size down to about 70-80% of the size of untreated controls was found in mice treated with 
rapamycin and PhA. Interestingly, a comparable effect was observed for chondramid B and soraphen 
A. However, the strongest impairment was observed for epothilon B and pretubulysin D, both of 
which resulted in a complete regression of the tumor growth (Fig. 3.20A and B).  
Moreover, the drug-mediated reduction of invasiveness of rKSHV-HuARLT cells in the 3D cell 
culture conditions strongly correlates with tumor size reduction (R2=0,9266, Fig. 3.20C). In contrast, 
viral copy number reduction, measured both in 2D and 3D cell culture show poor correlation with the 
in vivo outcome (R2=0.0863 and 0.0517 respectively). Taken together these observations highlight the 
predictive power of the 3D invasiveness assay with respect to tumor size reduction in vivo. 
Figure 3. 20  Evaluation of novel compounds for viral loss and cellular invasiveness. 
A) Natural compounds inhibiting KSHV lytic reactivation in BJAB cells. A library of natural compounds was screened for 
the ability to reduce the production of infectious virus by lytically induced KSHV-infected BJAB (Brk.219) cells. The 
amount of infectious virus released from Brk.219 cells was measured by plating supernatants on HEK293 cells and 
measuring the GFP signal in a BioTek plate reader. Replicates are depicted (Data from T. Schultz and G.Beauclair). (B-E) 
Selected compounds were tested on rKSHV-HuARLT cells. The relative viral load was assessed in rKSHV-HuARLT cells 
upon culture in presence of the indicated drugs in standard 2D conditions (B) or in 3D matrigel (C). Non-treated cells were 
included as reference (control). 40% viral copy reduction in viral copy number was chosen as a cut-off value to select active 
compounds (dashed line). D) rKSHV-HuARLT cells were treated with the compounds in 3D cell culture conditions. The 
relative sprouting index was determined after 2 weeks treatment. 40% reduction on sprouting index viral copy reduction was 
chosen as a cut-off value for active compounds (dashed line). For drug concentrations used in this experiment see Table 2.8. 
Control compounds are indicated in green. Statistical significance is shown by asterisks: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 
0.001, **** p ≤ 0.0001. E) Heat map summarizing the activity of the compounds in indicated assays (some of the 
compounds were tested by A. Lieske).  
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Figure 3. 21  Compound validation in vivo. 
A) Representative immunohistochemistry sections from lesions observed without treatment or upon 4 weeks treatment with 
indicated compounds. Cells were stained for human vimentin, scale bar 200 µm. Scale bar 200 µm. B) The lesion size was 
measured and is indicated as % of non-treated control (n=6 per compound). 25% tumor size reduction was chosen as a cut-
off value for active compounds. Statistical significance is shown by asterisks: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, ****  p 
≤ 0.0001, (10 to 80 lesions out of 6 plugs). C) Correlation analysis of 3D sprouting index vs. lesion size diameter in vivo. 
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4. Discussion 
Immunocompromised patients, as patients with HIV or organ recipients, have higher risks of 
developing Kaposi’s sarcoma than the general population. Currently there are about 36,7 million 
people living with HIV with an estimated 1,8 million of newly infected patients per year 
worldwide236. With the recent development of organ transplantation, the amount of transplantations 
increases worldwide237. This statistics indicates that high-risk groups for developing KS continue to 
grow and highlights the need for efficient anti-KS therapeutics. The current therapies of Kaposi’s 
sarcoma are mainly based on standard antitumor treatments, and have several limitations, such as high 
overall toxicity, low efficiency, and strong side effects. Currently there is no targeted therapy and no 
vaccines available. While some drugs that block the virus in its lytic stage have been discussed 
recently124, the latent stage of the virus that is predominant in KS lesions can so far not be specifically 
targeted. 
Since KSHV infection is restricted to humans, investigation of KS pathogenesis as well as the 
development of novel therapeutics relies on model systems that aim to recapitulate viral-induced cell 
transformation in vitro and therefore can be predictive for in vivo outcome. In this study, the 
properties of the previously developed conditionally immortalized human endothelial cell line 
HuARLT194 were investigated upon KSHV infection. 
4.1. HuARLT cells as a model for KSHV infection 
HuARLT cells were generated based on primary human umbilical vein endothelial cells (HUVECs)193 
commonly used in endothelial cell research. HUVECs represent blood endothelial cells (BECs) in 
classic 2D cell culture conditions, but they exhibit certain plasticity and transdifferentiation towards 
lymphatic linage in 3D cell culture conditions238. HuARLT cells represent a tightly growth-controlled 
cell line that preserves the phenotype of the primary cells. This is reflected both by the expression 
profile as well as the functional properties, such as the uptake of macromolecules and tube formation 
in Matrigel assay193. Importantly, the cells are able to form functional perfused blood vessels upon 
transplantation in Rag2-/-γc-/- mice. No aberrant cell proliferation and no tumor formation is detected 
upon transplantation of HuARLT even upon prolonged obsevation194. Similar to primary cells, 
HuARLT increased the expression of endothelial-specific markers upon growth arrest (Fig. 3.2A and 
B). Uptake of macromolecules, as well as tube formation, was more efficient in non-proliferating 
cells, suggesting that growth-arrested cells more closely reflect endothelial phenotype (Fig. 3.2D and 
E, 3.6). The use of primary cells in drug screening is limited due to high donor-to-donor variability 
and limited cell numbers. HuARLT cell line overcomes these limitations and represents an 
expandable, reproducible cell culture system.  
HuARLT cells are susceptible for KSHV infection and like the cells within Kaposi’s sarcoma239–241 
the majority of rKSHV-HuARLT cells established latency upon infection with KSHV. Similar to 
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other adherent cell lines upon infection159,160, rKSHV-HuARLT cells could not be efficiently 
reactivated with the use of TPA or epigenetic modifiers, such as sodium butyrate or decitabine. 
KSHV induced a number of functional and transcriptional changes in the infected cells. These 
changes mainly affected genes associated with cell migration, innate immune response and cell 
differentiation, as assessed by transcriptome analysis (Fig. 3.5 A and B). Although HuARLT cells 
expressed a number of BEC-specific markers, such as VEGFR1, Tie1, Tie2 and VE-Cadherin, the 
expression was abrogated upon KSHV infection and the expression of LEC-specific markers, such as 
POX1 and VEGFR3, increased (Fig. 3.5 C-E). These changes reflect endothelial transdifferentiation 
observed upon infection of primary cells and typical for spindle cells within KS tumors, which 
express both BEC and LEC markers. Further, this study showed that they critically depend on 
PI3K/Akt/mTOR and NF-κB pathways which have been shown to provide a survival advantage to 
infected cells141. 
Unlike HuARLT cells, rKSHV-HuARLT cells form KS-like lesions upon transplantation to Rag2-/-γc-
/- mice, opening the opportunity to investigate the fate of infected cells in vivo194. In situ hybridization 
with Alu polymerase showed that the lesions were originated from human cells. Majority of the cells 
carried the virus, as was demonstrated by immunohistochemistry staining for LANA and virus-
encoded GFP, as well as FACS analysis (Fig. 3.8 C and Fig. 3.11 B). Similar to KS biopsies242 and 
KSHV-infected SKL cells243, the lesions were positive for the human thrombomodulin (CD141), 
which is recognized as a marker of lymphatic endothelium and expressed in many endothelium-
derived tumors244 (Fig. 3.8 C). Tumorigenic phenotype was recapitulated in 3D fibrin cell culture, 
where rKSHV-HuARLT cells showed increased invasiveness and loss of vessel formation, as 
compared to non-infected cells. 
Notably, the overall expression of pan-endothelial genes245 is decreased upon infection194, whereas the 
transcriptome analysis indicated changes in genes connected with cell motility (Fig. 3.5 A and B). 
Together with the loss of the ability of infected cells to form vessels, the increased migration, and 
acquired invasiveness of infected cells in 3D culture and in vivo, these transcriptional changes indicate 
that the cells lost their endothelial properties and underwent endothelial-to-mesenchymal transition, 
typical for KS lesions and KSHV-infected primary cells84,86.  
Increased and aberrant angiogenesis with extravasated erythrocytes is a key feature of Kaposi’s 
sarcoma lesions. KSHV is able to induce angiogenesis by a complex interplay of viral and cellular 
pro-angiogenetic and pro-inflammatory signaling affecting both KSHV-infected cells as well as 
neighboring cells in paracrine manner49,246. Interestingly, although rKSHV-HuARLT lost the ability to 
form vessels in 3D fibrin gels and upon transplantation to mice, the cells showed increased tube 
formation in the matrigel tube formation assay in agreement with previous studies in primary KSHV-
infected cells122,247.  
Matrigel tube formation assay is typically employed to demonstrate the angiogenic activity of 
vascular endothelial cells in vitro. However, recently it has been shown that the tumor cells, such as 
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melanoma B16F1 cells, glioblastoma U87 cells, and breast cancer MDA-MB-435, are able to form 
tube-like structures in Matrigel assay248. Thus, matrigel tube formation assay is not specific for 
endothelial sprouting and can also be used also to study vasculogenic ability of tumor cells, referred to 
as vasculogenic mimicry. Likely, the ability of rKSHV-HuARLT cells to form tubular network in the 
matrigel assay might represent the ability of the infected cells to employ alternative angiogenetic 
mechanisms and cannot be considered as an increased endothelial function. 
Taken together, the results of this study give further evidence that HuARLT cells reflect the properties 
of primary cells upon KSHV infection. The cells undergo transcriptional reprogramming as well as 
acquire an invasive and tumorigenic phenotype recapitulating the changes observed in patients, thus 
highlighting the relevance of the cell line for investigation of KSHV pathogenesis and the validation 
of novel antiviral compounds. 
4.2 Tumorigenicity of the cells depends on virus gene expression 
While it has been shown that the plasma level of KSHV is a poor prognostic or diagnostic biomarker 
for KS249,250, it was highlighted that rather the viral load within tumor cells correlates with the tumor 
burden in the patients and reflects the severity of the disease250. This suggests that the reduction of 
viral load within KSHV-infected cells may result in loss of tumorigenic potential.  
To test this hypothesis, in this study a virus-free cell population was established by passaging rKSHV-
HuARLT cells in absence of selection pressure. The virus free cell population was characterized by an 
altered transcription profile and the main changes include deregulation of the genes associated with 
cell migration, angiogenesis and innate immune response (Fig.3.18 C and D). The transcriptome 
changes corresponded to a change of the in vivo phenotype, as the virus-free cell population lost its 
tumorigenic potential upon transplantation in vivo (Fig. 3.18 E).  
While some systems have been used before to establish KS-like lesions in nude mice upon 
transplantation of the cells carrying KSHV genome161,185–187, this study shows for the first time  that 
the cellular phenotype can be reverted upon purging the cells from the virus. Thus, the expression of 
viral genes, rather than the permanent virus-induced cell transformation is essential for KSHV-
induced tumorigenesis. Since the virus-induced changes are reversible when the cells are cured 
targeting the pathways effecting viral maintenance in latently infected cells can be considered to be a 
viable strategy for treatment of KS. 
Studies indicate that viral proteins induce genomic instability both directly251–253 or via manipulation 
of DNA damage response (reviewed in105). This process may lead to irreversible cell transformation 
and undoubtedly contributes to KSHV-induced tumorigenesis on later stages. Still, this study 
indicates that at least on early stages of KS development expression of viral genes is necessary and 
sufficient to induce tumorigenesis.  
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4.3 Molecular mechanisms of viral maintenance 
Clinical data suggest that the amount of KSHV infected cells59 as well as the KSHV burden within the 
tumor increases with the progression of the disease250. Surprisingly, in vitro studies showed that 
although spindle cells in KS carry the KSHV genome directly after isolation, they fail to retain it in 
2D culture153–155. Similarly, primary endothelial cells156 as well as the majority of telomerase-
immortalized endothelial cells161 rapidly lose the KSHV genome upon cultivation.  
It has been hypothesized that viral loss in endothelial cells is a result of cell proliferation and 
inefficient viral replication. This would also imply that not endothelial, but rather non-proliferating 
memory B cells are the main reservoir of KSHV156. HuARLT cells are tightly growth controlled with 
less than 1% proliferating cells in absence of doxycycline, as measured by Ki67 staining (Fig. 3.1 C 
and D). In order to test, if cell proliferation affects viral maintenance, viral copy number was 
evaluated in proliferating and growth-arrested conditions. No difference in viral copy number was 
observed (Fig. 3.10), demonstrating that viral loss upon cultivation in 2D cell culture conditions is not 
the result of cellular proliferation. Moreover, efficient maintenance of the virus in 3D conditions and 
upon transplantation in vivo indicates that 3D cell culture conditions (Fig. 3.11) are beneficial for 
virus persistence. Together with the observation that 3D cell culture conditions better reflect EndMT, 
as addressed by changes in transcriptional profile86 as well as invasive phenotype, the results of this 
study indicate higher relevance of 3D cell culture systems for investigation of viral pathogenesis. 
4.3.1 Viral reactivation in 3D cell culture conditions 
Previous studies showed higher levels of lytic reactivation in 3D cultivated B cells172 and endothelial 
cells86. KSHV viral copy number in 3D cell culture was markedly reduced upon treatment with 
phosphonoformic acid (Fig. 3.12 A), an inhibitor viral DNA polymerase136, suggesting that lytic 
reactivation contributed to the efficiency of viral maintenance. Surprisingly, neither the expression of 
lytic genes addressed by RT-qPCR, nor PAN-driven RFP expression, was increased in 3D cell culture 
conditions (Fig 3.12 B and C). The discrepancy between the results can be explained by different 
sensitivity of the methods. Histological data indicate that only a minor fraction of the cells with KS 
lesions undergo spontaneous reactivation68. Based on these observations only few percent of KSHV 
infected cells are expected to reactivate at the time, which would not be possible to detect via RT-
qPCR due to the dilution of the signal in the latent population. Moreover, some reports indicate that 
virus-encoded fluorescence proteins do not always reflect the infection status correctly, likely due to 
variable episomal silencing and different expression dynamic compared to ‘native’ viral genes.254,255. 
Besides, lytically reactivated cells undergo apoptosis, and therefore are likely to be washed or gated 
out during sample preparation and FACS analysis, which could explain the inability to detect the RFP 
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positive cells in 3D cultures. Therefore, the lack of any prove for a lytic state based on these two 
methods can not exclude a small proportion of reactivating cells in the 3D culture.  
In contrast, continuous treatment with PhA, the inhibitor of lytically expressed DNA polymerase, 
would affect all reactivating cells thought-out the prolonged treatment. Therefore it had more 
prominent cumulative effect on the inhibition of viral replication and was more likely to be detected. 
Thus, reduction of viral copy number in 3D cell culture by PhA indicated that viral lytic replication at 
least partially contributes to viral maintenance in 3D cell culture.  
Interestingly, the cells cultured in 3D conditions showed consistent downregulation of the genes 
encoded on the viral episome. Considering that both latent and lytic genes, as well as virus encoded 
GFP driven by a cellular promoter, are downregulated in a similar fashion (Fig. 3.12 C-G), it is 
tempting to speculate that the viral episome is kept in an altered epigenetic state in 3D cell culture 
conditions. Additional studies would be required to confirm this hypothesis and to determine if the 
epigenetically altered viral episome has an effect on viral maintenance. 
4.3.2 Role of the PI3K pathway in KSHV maintenance 
In order to determine which cellular pathways are differentially expressed in 2D and 3D cell culture 
conditions, and therefore might be responsible for increased viral maintenance, transcriptome analysis 
of the cells was carried out. As a result, a prominent alteration of the PI3K/Akt/mTOR pathway was 
detected (Fig. 3.14 B). The specific pharmacological inhibition of PI3K and mTOR could confirm that 
the pathway is crucial for viral maintenance in 3D, but not in 2D cell culture (Fig. 3.14 D). 
Several studies indicate that the PI3K pathway is involved in KSHV reactivation upon coinfection 
with HIV or Herpes Simplex virus type 1. Inhibition of the pathway leads to lack of viral reactivation 
in these conditions38,39. Higher levels of PI3K in 3D cell culture conditions might thus enable lytic 
reactivation and therefore result in more efficient viral maintenance. 
The other studies show that PI3K pathway is activated as early as 5 minutes p.i. PI3K activation leads 
to the Rho-GTPase dependent assembly of microtubules, their association with the viral genome, and 
its transfer to the nucleus. Pharmacological inhibition of the PI3K pathway results in lower efficiency 
of infection20. 3D cell culture provides more favorable conditions for virus spread due to cell 
compaction and increased cell-cell contacts. Of note, inhibition of the lytically expressed viral DNA 
polymerase in 3D cell culture results in loss of viral copies, indicating that the better viral 
maintenance in 3D cell culture is likely due to higher virus production and dissemination. In that case, 
activated PI3K pathway would not only support viral reactivation, but also assure better cell-to-cell 
transmission. 
Besides direct interaction with KSHV PI3K/mTOR pathway regulates various cellular processes that 
might impact viral replication, such as cellular metabolism, autophagy, and protein synthesis. 
Autophagy is shown to restrict viral infection and initiate antiviral immune response by cooperating 
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with pattern recognition receptors256. It is a key part of viral pathogenesis for several human 
pathogens, including Zika virus257. To test if differential regulation of autophagy by PI3K contributes 
to differential viral maintenance in 2D and 3D cell culture, the expression of autophagy-associated 
genes was analyzed by RNA-Seq. The analysis showed no difference in expression of genes in neither 
Autophagy database258 comprising 1383 genes nor HADb259 comprising 232 genes (data not shown). 
This data indicate that it is unlikely that autophagy contributes to differential KSHV maintenance in 
2D and 3D cell culture. 
A recent study by McCormick showed that although mTOR is crucial for early stages of viral 
reactivation, its role in viral protein synthesis is dispensable260. The study demonstrated that 
translation efficiency of viral proteins is independent from eIF4F and, therefore from mTOR. This 
suggests that the differences observed in 2D and 3D might probably also not be attributed to 
regulation of protein synthesis by mTOR. 
4.3.3 DNA Damage response and its role in viral maintenance 
Differential viral maintenance in 2D and 3D cell culture could be a result of two independent 
processes, namely, an increase of viral replication in 3D cell culture or viral degradation in 2D 
conditions. Detection and specific degradation of episomal viral genomes by the cell thus represents 
an antiviral strategy. An increasing body of evidence suggests that DNA damage response can serve 
as a part of an intrinsic intracellular defense against viruses. KSHV triggers the DDR on various 
stages on viral infection and complex interactions between DDR and KSHV is illustrated in Fig.4.1. 
The detection of viral DNA by DDR sensors leads to the induction of several innate immune 
pathways, such as type-1 interferon and NF-kB.  
Of note, a differential expression of genes associated to the DNA damage response pathway was not 
detected via RNA-Seq analysis (data not shown). However, this does not argue against an 
involvement of this pathway since the regulation of the pathway is mainly realized on the 
posttranscriptional level, such as protein phosphorylation, and therefore cannot be evaluated on the 
transcriptional level. Accumulating evidence shows that the activation of PI3K/Akt/mTOR regulates 
the DNA damage response. In the following, several hypotheses are discussed that might explain the 
contribution of DDR to differential viral maintenance in the various culture conditions, thereby 
including results from the current study as well as reports from literature. 
A. The role of ATM and γH2AX  
Histological studies indicate that markers of DNA damage response, such as γH2AX, pT-Chk2 and 
53BP1, are also activated in early KSHV lesions261. H2AX phosphorylation (γH2AX), a marker of 
DNA damage response activation, can be detected as early as 30 minutes post-infection in primary 
endothelial cells and colocalizes with viral DNA108. The binding of γH2AX to TRs enables the 
tethering of viral episome to cellular chromatin via direct interaction between γH2AX and C-terminal 
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domain of LANA. The interaction is crucial for the establishment and maintenance of KSHV latency 
and its disruption, either by inhibition of H2AX phosphorylation or by mutation of the interaction 
cites, leads to the reduction of the viral copy number108,262.  
In line with this literature data, viral copy number can be significantly reduced by treatment with 
Ku55933, a small molecule inhibitor of the ATM (Fig. 3.16 B). This data confirms that ATM activity 
supports maintenance of latency both in 2D and 3D cell culture conditions.  
  
Figure 4. 1  Summary of the interplay between KSHV and DNA damage response during viral latency and reactivation 
(based on literature data). 
B. The role of Eya phosphatases 
Of note, while the expression of H2AX did not change from 2D to 3D cell culture conditions, the 
expression levels of Eya1, 2, and 4 are markedly reduced in 3D cell culture of rKSHV-HuARLT cells, 
as addressed by RNA-Seq and RT-qPCR (fig. 3.17 A and B). Recent studies suggest that 
phosphorylation at the Tyr142 site of H2AX determines cell death or DNA repair decisions by 
regulating the binding of apoptotic proteins and proteins responsible for DNA repair93. This 
observation led to the hypothesis that an increased expression of Eya in 2D cell culture conditions 
might restrict KSHV maintenance by an unknown mechanism. To test this hypothesis, the cells were 
treated with MLS000544460, a small molecule inhibitor of Eya2, but not the other Eya 
phosphatases233. This inhibitor was chosen as the only commercially available inhibitor of Eya 
phosphatases. If Eya2 activity were restrictive for viral maintenance in 2D, the treatment would 
increase the viral copy number. In contrast, the treatment with the inhibitor lead to the minor decrease 
in viral copy number, suggesting that Eya2 might be supportive for viral maintenance in 2D cell 
culture (Fig. 3.17 C). Of note, the expression levels of Eya2 was the lowest among the four 
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phosphatases (data not shown) and Eya1 showed the highest fold change in 3D cell culture conditions. 
Therefore, to finally exclude or confirm the role of the Eya phosphatases additional studies with more 
selective inhibitors or  knockout/knockdown should be done.  
C. Impact of the DNA dependent protein kinase DNA-PK 
The DNA-PK complex, a heterotrimeric complex consisting of the Ku70/Ku80 heterodimer and the 
catalytic subunit of the DNA dependent serine protein kinase DNA-PK, was identified as a 
cytoplasmic sensor for DNA that is important for the innate immune response to intracellular DNA101. 
Lytic reactivation of KSHV induces ATM-CHK2 and DNA-PK response, but not ATR-CHK1, and 
inhibition of DDR kinases results in alterations of virus production in B cells263. Recent studies 
showed that knockdown or inhibition of Ku70/Ku80 or DNA-PK enhances the amplification of 
KSHV DNA, indicating that DNA-PK restricts viral replication upon lytic reactivation in the 
endothelial cell line EA.hy926232. In contrast, when the DNA-PK activity was blocked in latently 
infected rKSHV-HuARLT cells a reduction in viral copy number was observed, indicating that the 
complex supports latent viral maintenance. Moreover, no difference was observed for 2D and 3D 
culture conditions, suggesting that DNA-PK is not responsible for the differential maintenance of 
viral genomes.  
D. The role of the MRN complex 
Another factor contributing to DDR is the MRN complex. RPA32 and Mre11 localize to the sites of 
viral DNA synthesis during viral reactivation263. So far, its role in KSHV is controversial.  One study 
showed that inhibition of the MRN complex by a small molecule leads to a decrease in virus 
production in lytically reactivated endothelial cells232 suggesting a beneficial role of MRN for lytic 
replication. On the contrary, another study showed that the silencing of the MRN complex leads to 
increase of KSHV lytic replication in an NF-κB dependent manner in KSHV-infected B cells109. In 
addition, the study showed that LANA recruits the MRN complex to the cytosol and antagonizes 
MRN-induced innate immune response against KSHV, thus supporting lytic reactivation in HeLa and 
B cells109. This suggests that the MRN complex impairs lytic reactivation. Interestingly, when the role 
of the MRN complex was studied in rKSHV-HuARLT cells the pharmacological inhibition of MRN 
by mirin (Fig. 3.16) showed no effect in 3D cell culture. At the same time, the treatment showed a 
moderate increase in viral copy number in 2D cell culture. This observation thus supports the idea that 
the MRN complex has a restrictive role on KSHV maintenance in 2D cell culture (Fig 4.2 A). 
However, since pharmacological inhibitor studies are limited due to dose restriction, toxicity, and off-
target effects, more detailed studies with a specific knockout of the components of MRN complex are 
needed to confirm this conclusion. This might be achieved by introducing frame-shift mutations via 
CRISPR-Cas9 to Mre11, Rad50 or NSB1 genes.  
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The activation of PI3K/Akt/mTOR regulates the DNA damage response by degradation of MRN 
complex264 as well as imparing activity of RNF168, a E3 ligase, which is shown to be involved in 
H2AX ubiquitination and amplification of the DDR signal265. These data suggest that upregulation of 
the PI3K pathway in 3D cell culture may lead to downregulation of MRN dependent response and 
result in increased viral maintenance (Fig. 4.2 B). Together with increased viral reactivation and 
dissemination, regulation of MRN might be an additional mechanism by which PI3K/Akt contributes 
to KSHV maintenance in 3D cell culture. 
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Figure 4. 2  A scheme illustrating a hypothesis of PI3K-governed maintenance. 
PI3K supports KSHV reactivation and virus entry to neighboring cells. MRN-dependent viral degradation might explain 
loss of viral copies in 2D cell culture. Overactivation of PI3K pathway in 3D cell culture inhibits the effect of MRN 
complex supporting better viral maintenance.  
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4.4. rKSHV-HuARLT cells for testing of novel antiviral compounds 
Based on the rKSHV-HuARLT three in vitro tests for preselection of novel antiviral compound were 
developed, namely the viral copy number reduction in 2D and 3D cell culture and a 3D invasiveness 
assay. While 2D cell culture allowed selection of drugs targeting exclusively latent virus, 3D cell 
culture provided conditions in which both inhibitors of viral latent and lytic replication could be 
tested. The two assays were complemented with a 3D sprouting assay, which allowed direct 
assessment of the invasiveness of the cells in presence of the tested compounds. All three assay 
systems were validated by using compounds with known pharmacological targets, such as GA, PhA 
and rapamycin, targeting viral latent maintenance, viral DNA replication or KSHV induced 
invasiveness and angiogenesis, respectively. The fact that the compounds performed as predicted 
highlights the relevance of the system for validation of novel compounds.  
A selected set of natural compounds derived from a myxobacterial library was validated for antiviral 
and antitumor effects using standard and advanced cell culture assays. The combination of the results 
of 2D and 3D in vitro assays allowed the identification of potential therapeutic candidates. These 
compounds were finally challenged in a humanized mouse model that allows monitoring the tumor 
formation of KSHV-infected human endothelial cells.  
Interestingly, only the 3D invasiveness assay, but not the assays addressing viral copy number, 
showed high correlation with in vivo outcome, indicating high predictive power of the assay.  
Although 2D cell culture is a valuable tool for high throughput drug screening and target validation, it 
does not fully reflect virus-induced transformation of endothelial cells and it is insufficient for viral 
maintenance. 3D cell culture supports conditions under which the cells obtain a more invasive 
phenotype, as evident by transcriptome analysis, and are able to achieve a certain level of viral 
reactivation, sufficient for viral maintenance. KSHV-infected endothelial cells show increased 
invasiveness and angiogenesis and these effects are dependent on several viral proteins expressed 
either during the latent (e.g. LANA266–269, vFLIP270, vCyc271) or lytic (e.g. vIL-6272,273, vGPCR274,275, 
K1276, K15121,277) phase of the viral life cycle. Lytically expressed viral cytokines induce angiogenesis 
and invasiveness both in autocrine and paracrine manner. The drugs inducing viral loss are likely to 
target either viral latent genes, or viral DNA replication machinery, but not necessary have an effect 
on viral cytokines, which are not necessary for viral latent or lytic replication. This might explain why 
a simple viral copy number reduction in 2D cell culture has very poor correlation with the antitumor 
effect of the drugs in vivo. However, poor correlation with in vivo outcome may also be a result of 
non-representative drug selection. Due to restrictions in animal law, only compounds with known 
pharmacokinetics and pharmacodynamics could be tested. As a result, the drugs selected for the in 
vivo study did not include the novel compounds with the strongest effect on the viral copy number 
reduction.  
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Still, even these drugs showed a strong correlation between sprouting in 3D cell culture and tumor 
size reduction in vivo. However, both assays do not allow distinguishing between antitumor and 
antiviral effect of the compounds and are sensitive not only to the KSHV-specific drugs, but also to 
the drugs targeting cell motility, proliferation or survival. This highlights the need for combination of 
virus-specific test systems with highly predictive 3D assays for faithful pre-selection of active 
compounds in vitro. 
Four compounds (tubulysin Y, pretubulysin D, epothilon B and stigmatellin A) that did not reduce the 
viral copy number but were efficient in reducing sprouting were identified with the use of the system. 
Tubulysin Y, pretubulysin D and epothilon B are known to interact with the cytoskeleton by acting on 
tubulins, thereby inducing apoptosis of proliferating cells214,215,217,278,279, a property that qualifies these 
drugs as antitumor agents. Both epothilon B and pretubulysin D abolished tumor formation in the 
xenograft mice, which qualifies them as novel therapeutic options against KS. Although the 
compounds showed no KSHV-specific effect, they efficiently reduce tumor formation in vivo, 
outperforming rapamycin, a drug that is in clinical use for KSHV-infected organ transplant recipient 
with KS. 
The tests also identified chondramid B that induced a moderate, but significant tumor size reduction 
comparable with the effect of rapamycin. This effect is in line with previously published data, 
characterizing chondramid B as an actin-polymerizing myxobacterial compound diminishing 
angiogenesis in vitro and in vivo213. Interestingly, in the assays chondramid B also significantly 
reduced the viral copy number in 2D and 3D cell culture, which suggests that in addition to 
antiangiogenic properties it has a specific antiviral effect. While it remains to be elucidated if the 
effect of chondramid B depends on its function on actin or is a result of the interaction with other 
molecular targets, these findings highlight chondramid B as a potential novel anti-KSHV therapeutic. 
Animal tests play a crucial role in drug development, because they allow not only the confirmation of 
selective drug activity, but also access its pharmacokinetics, pharmacodynamics and safety in vivo. 
Humanized mouse models expand the toolbox and allow us to study human-specific diseases, like 
Kaposi’s sarcoma, as well. In this study a novel humanized mouse model was developed which allows 
testing of novel compounds that inhibit KSHV induced tumor growth. However, animal experiments 
remain constrained by ethical considerations, are laborious and cost-intensive. In this regard, 
predictive in vitro tests are required to limit the requirement of animal experiments to a minimum. 
This will allow reducing the numbers of experimental animals and ensure compliance with 3R 
principles. 
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5. Outlook 
This study showed that HuARLT cells reflect the properties of primary endothelial cells upon 
infection with KSHV, thus confirming that the cell line represent a reliable and scalable system for 
investigation of KSHV infection and screening of potential antiviral drugs.  
In depth characterization indicated that viral maintenance is dependent on cell culture conditions and 
on the activity of the PI3K/mTOR pathway. Regulation of MRN stability by mTOR might represent 
one of the molecular mechanisms governing viral stability in 3D cell culture, however the results have 
to be confirmed with the other methods. Also, the detailed molecular mechanisms that govern MRN-
dependent virus degradation need to be further investigated.  
The system was used to validate anti-KS activity a selection of natural metabolites. To this end, the 
ability of the compounds to reduce viral load and invasiveness of the infected cells was evaluated in 
vitro. Based on the in vitro performance, three compounds were selected for test in humanized mouse 
model. In vivo tests revealed that the selected compounds reduce tumor size with similar or greater 
effect than rapamycin, which is clinically used to treat post-transplantation KS. This result shows the 
power of the system to validate novel potent KS therapeutics. Two out of the compound, which 
showed high potency in vivo, have no effect on KSHV maintenance, indication that they might not 
antiviral, but rather antitumor drugs. Screening of a bigger compound library will allow identification 
of specific antiviral compounds and establishment of targeted KS therapy. 
This study showed that HuARLT cell line closely mimicked the properties of primary endothelial 
cells and allowed investigation of endothelial-specific infection in vitro and in vivo. This indicates the 
potential of the system to be extended to other endothelial-specific pathogens. In particular, the cell 
line is permissive for human cytomegalovirus infection and the cells support full replication cycle of 
the virus. With the use of the cells line the change of the cellular phenotype upon hCMV infection can 
be further investigated. Similar to KSHV, hCMV is a human-specific virus and therefore has no small 
animal model available. The potential of HuARLT cells to mimic hCMV infection in vivo and be 
used for validation of novel hCMV drugs has to be evaluated in the further studies.  
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